US20150122687A1 - Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage - Google Patents
Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage Download PDFInfo
- Publication number
- US20150122687A1 US20150122687A1 US14/533,922 US201414533922A US2015122687A1 US 20150122687 A1 US20150122687 A1 US 20150122687A1 US 201414533922 A US201414533922 A US 201414533922A US 2015122687 A1 US2015122687 A1 US 2015122687A1
- Authority
- US
- United States
- Prior art keywords
- heart valve
- bioprosthetic heart
- adaptive seal
- hydrogel
- adaptive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
- A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
-
- A61B19/026—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0095—Packages or dispensers for prostheses or other implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A61B2019/0201—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
- A61B2050/002—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers having adhesive means, e.g. an adhesive strip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
- A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
- A61B50/33—Trays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0069—Sealing means
Definitions
- the invention relates to a heart valve prosthesis and, more particularly, to a heart valve prosthesis having an adaptive seal that minimizes perivalvular leakage following implantation.
- PVL Perivalvular leakage
- Intimate apposition of replacement heart valves and the surrounding cardiac or arterial walls seals the valve and minimizes PVL. In certain cases, however, a seal cannot be achieved, leaving irregular gaps of different sizes and shapes between the valve and the cardiac or arterial walls. This may result from inadequate sizing, incomplete expansion of the valve, an irregularly deformed valve, or highly eccentric or irregular calcification pattern on the leaflets or valve annulus.
- PVL has been shown to greatly affect the clinical outcome of transcatheter aortic valve replacement procedures, and the severity of perivalvular leakage has been correlated with patient mortality. What is therefore needed is a replacement bioprosthetic heart valve which permits a conforming engagement or fit with the surrounding cardiac or arterial wall so as to substantially fill in the gaps or channels that often result in PVL.
- Bioprosthetic heart valves having the adaptive seals described herein are preferably valves which comprise a biological tissue that has been treated so as to not require storage in liquid preservative solutions. While mechanical heart valves are capable of being stored in a dry state, valves having biological tissue typically require storage in liquid preservative solutions. Storage in liquid preservative solutions introduces a host of challenges for valves which include adaptive seals, particularly for those which are activated to expand upon exposure to liquid.
- the bioprosthetic heart valves disclosed herein in which the biological tissue is treated so as to permit dry storage of the valves without a liquid storage solution.
- the adaptive seals can be exposed on the heart valve without requiring encapsulation or a barrier from the environment, as would be required if the valves were to be stored in a liquid preservation solution.
- the adaptive seals can simply comprise the expandable material exposed or contained within a permeable or semi-permeable material that permits fluid to come into contact with the expandable material, while supporting or containing the expandable material.
- the replacement heart valve or the adaptive seal is not selectively encapsulated by a non-permeable barrier.
- the simplicity of being able to provide an adaptive seal structure, without selective encapsulation, provides significant advantages over prior art heart valves in which the selective encapsulation of the adaptive seal in a liquid storage solution is a necessity.
- the selective encapsulation methods of the prior art are required to permit the tissue portion of the valve to be in contact with the liquid storage solution while at the same time segregating the adaptive seal portion from the liquid storage solution. If the adaptive seal is not selectively encapsulated from the liquid storage solution, it will expand and render the heart valve unusable.
- the bioprosthetic heart valves contemplated within this disclosure can be any implantable heart valve which preferably comprises a biological tissue.
- Such valves include transcatheter valves, surgical valves, minimally-invasive valves, and the like.
- the biological tissue can be derived from animal sources, preferably, from pericardial tissue, and most preferably, from bovine pericardial tissue.
- the biological tissue is used to form the leaflets of the heart valve and is mounted to a supporting frame or stent to form a bioprosthetic heart valve. Because the valves are stored dry, the biological tissues are treated so as to preserve their pliability and flexibility in a dry state, e.g., without storage in a liquid storage solution.
- dry or “dehydrated”, as used herein, are understood to include residual moisture or humidity from the ambient environment and is intended to mean that the valves are not immersed in, or in contact with, a liquid or a storage solution.
- a method for manufacturing a bioprosthetic heart valve comprises providing a bioprosthetic heart valve comprising a biological tissue that has been treated with a treatment solution comprising a polyhydric alcohol, the bioprosthetic heart valve having a periphery, an inflow portion and an outflow portion.
- the method further comprises coupling an adaptive seal to the bioprosthetic heart valve, the adaptive seal comprising an expandable material that expands after exposure to an initiating condition.
- the method further comprises packaging the bioprosthetic heart valve and the coupled adaptive seal in a package that does not contain a liquid storage solution in contact with the bioprosthetic heart valve and the coupled adaptive seal.
- the adaptive seal is not further encapsulated, segregated or enclosed from the biological tissue.
- the polyhydric alcohol is glycerol.
- the biological tissue is at least partially dehydrated following treatment with the treatment solution.
- the adaptive seal is a hydrophilic polymer or a hydrogel-coated wire.
- the hydrophilic polymer or the hydrogel-coated wire comprises a biodegradable cross-linker. Expansion of the adaptive seal is delayed for a period of time after exposure to the initiating condition.
- the initiating condition is one or more selected from the group consisting of: a change in temperature, a change in the electrical field, a change in the magnetic field, a change in the chemical environment, a change in pH, and contact with a liquid.
- the expandable material expands longitudinally, radially, or both longitudinally and radially relative to the bioprosthetic heart valve after exposure to the initiating condition.
- the bioprosthetic heart valve comprises a stent and the coupling comprises coating the stent with the adaptive seal or coupling patches within open cells defined by the stent.
- a packaged bioprosthetic heart valve comprises a bioprosthetic heart valve, an adaptive seal coupled to the bioprosthetic heart valve, and a sealed package containing the bioprosthetic heart valve and the adaptive seal.
- the bioprosthetic heart valve comprises a dehydrated biological tissue leaflet structure coupled to a supporting frame, the bioprosthetic heart valve having a periphery, an inflow portion, and an outflow portion.
- the adaptive seal comprises an expandable material that expands after exposure to an initiating condition.
- the sealed package containing the bioprosthetic heart valve and the adaptive seal does not contain a liquid storage solution in contact with the bioprosthetic heart valve and the adaptive seal.
- the adaptive seal is a hydrophilic polymer or a hydrogel-coated wire.
- the adaptive seal is a hydrogel comprising a biodegradable cross-linker and expansion of the adaptive seal is delayed for a period of time after exposure to the initiating condition.
- the adaptive seal is a hydrogel-coated wire comprising a shape memory metal, the hydrogel-coated wire changing from a first configuration to a second configuration upon reaching or exceeding a transformation temperature.
- the hydrogel-coated wire in the first configuration, has one of a straight or a coiled configuration and in the second configuration, the hydrogel-coated wire has the other of the straight or coiled configuration.
- the adaptive seal is coupled to the bioprosthetic heart valve at a spaced distance from both of the inflow and outflow portions.
- the adaptive seal is provided circumferentially about the bioprosthetic heart valve.
- the bioprosthetic heart valve further comprises a sewing ring and the adaptive seal is coupled to and exposed from the sewing ring or contained within the sewing ring.
- the supporting frame is a stent comprising a plurality of struts and open cells.
- the adaptive seal is coupled to one or more struts of the supporting frame.
- the adaptive seal forms one of a coating on at least a portion of the stent.
- the adaptive seal is provided as patches disposed within the open cells defined by the stent.
- FIG. 1A is a side view of an embodiment of an implanted bioprosthetic heart valve with an adaptive seal in a substantially unexpanded state.
- the arterial walls are cut away to show the gaps between the implanted bioprosthetic heart valve and the arterial walls.
- FIG. 1B is a plan view of the outflow portion of the implanted bioprosthetic heart valve of FIG. 1A showing the adaptive seal in a substantially unexpanded state within the arterial walls.
- FIG. 2A is a side view of the implanted bioprosthetic heart valve with the adaptive seal in a substantially expanded state.
- the arterial walls are cut away to show the adaptive seal expanded to fill at least some of the gaps between the implanted bioprosthetic heart valve and the arterial wall.
- FIG. 2B is a plan view of the outflow portion of the implanted bioprosthetic heart valve showing the adaptive seal in a substantially expanded state, with the arterial walls cut away to reveal the implanted bioprosthetic heart valve.
- FIG. 3A is a perspective view of the outflow portion of another embodiment of a bioprosthetic heart valve with the adaptive seal located about the periphery of the sewing ring.
- FIG. 3B is a perspective view of the inflow portion of the bioprosthetic heart valve of FIG. 3A .
- FIGS. 4A-4B are perspective views of an embodiment of a bioprosthetic heart valve in a collapsed and an expanded state, respectively.
- FIGS. 4C-4D are perspective views of another embodiment of a bioprosthetic heart valve in a collapsed and an expanded state, respectively.
- FIGS. 4E-4F are perspective views of a further embodiment of a bioprosthetic heart valve in a collapsed and an expanded state, respectively.
- FIG. 5A is an exploded perspective view of a further embodiment of a bioprosthetic heart valve showing the tissue valve portion and the stented sealing cloth.
- FIG. 5B is a perspective view of the bioprosthetic heart valve of FIG. 5A in which the tissue valve portion and the stented sealing cloth are assembled together.
- FIGS. 6A-6C are broken plan views of an embodiment of an expandable bioprosthetic heart valve and its delivery system in the various stages from a collapsed delivery configuration with the adaptive seal being adjacent the delivery system ( FIG. 6A ), an intermediate configuration with the adaptive seal is positioned around the bioprosthetic heart valve ( FIG. 6B ) and an expanded configuration, ready for full expansion of the adaptive seal ( FIG. 6C ).
- FIGS. 7A-7C are broken plan views of another embodiment of an expandable bioprosthetic heart valve and its delivery system in the various stages from a collapsed delivery configuration with the adaptive seal being adjacent the delivery system ( FIG. 7A ), an intermediate configuration with the adaptive seal is positioned around the bioprosthetic heart valve ( FIG. 7B ) and an expanded configuration, ready for full expansion of the adaptive seal ( FIG. 7C ).
- FIGS. 8A-8C are broken plan views of an expandable bioprosthetic heart valve and its delivery system in the various stages from a collapsed delivery configuration with the adaptive seal being adjacent the delivery system ( FIG. 8A ), an intermediate configuration with the adaptive seal is positioned around the bioprosthetic heart valve ( FIG. 8B ) and an expanded configuration, ready for full expansion of the adaptive seal ( FIG. 8C ).
- FIGS. 1A and 1B depict a transcatheter heart valve 100 that has been expanded and implanted within an arterial wall 1 .
- the transcatheter heart valve 100 generally comprises a biological tissue leaflet structure 110 that is coupled to an expandable frame or stent 120 . It is understood that the stent 120 can either be self-expanding or balloon-expandable.
- the heart valve 100 further comprises an inflow portion 102 , an outflow portion 104 and a skirt 125 that is coupled to the stent 120 , preferably by sutures, and located proximate the inflow portion 102 .
- the external peripheral surface of the heart valve 100 is shown to be in discontinuous engagement with the inner surface of the arterial wall 1 as shown by the gaps or voids 2 between them. These gaps result because the inner surface of the arterial wall 1 is typically an irregular surface.
- an adaptive seal 130 is provided around the external peripheral surface of the heart valve 100 .
- the adaptive seal 130 preferably comprises an expandable or swellable material, such as hydrogels (e.g., zwitterionic hydrogels), super absorbent polymers (SAPs), elastomeric materials or other swellable or absorbent polymer or elastomeric materials.
- the adaptive seal 130 does not comprise silicone or other lubricious materials or polymers that would potentially cause the implanted valve 100 to slip or dislodge from its initial site of implantation.
- the adaptive seal 130 can be coupled to the outer periphery of the stent 120 , as shown in FIGS. 1A and 1B , by adhesives or by one or more sutures. As can be seen in FIGS. 1-2 , the stent 120 further defines a plurality of open spaces or cells. Thus, the adaptive seal 130 can also be provided as a plurality of discrete patches that can be disposed within selected ones of the plurality of open spaces or cells defined by the stent 120 .
- the adaptive seal 130 has a substantially unexpanded length (A1-A1, FIG. 1A ) and a substantially unexpanded radial thickness (B1-B1, FIG. 1B ) upon initial implantation. Because the adaptive seal 130 will expand both along its length and radial thickness, it is preferably positioned around the heart valve 100 at a sufficient distance away from both the inflow portion 102 and outflow portion 104 such that the fully expanded adaptive seal 130 does not extend beyond the stent 120 . In addition, the adaptive seal 130 is constructed such that inward radial expansion into the lumen of the heart valve is limited, if not prevented. Thus, expansion of the adaptive seal 130 is preferably limited to the area between the outer periphery of the stent 120 and the arterial wall 1 .
- FIGS. 2A and 2B depict the transcatheter heart valve 100 of FIGS. 1A and 1B in which the adaptive seal 130 has expanded after exposure to an initiating condition.
- Expansion of the adaptive seal 130 takes place in a conforming, non-rigid manner and the adaptive seal 130 preferably expands in directions of least resistance, e.g., into the spaces or gaps 2 between the stent 120 and the arterial wall 1 .
- the expansion of the adaptive seal 130 takes place to a greater degree in areas where there are larger gaps between the stent 120 and the arterial wall 1 and to a lesser degree in areas where the gaps 2 are smaller.
- the adaptive seal 130 preferably expands along one or both of its longitudinal length (A2-A2, FIG.
- the adaptive seal 130 is shown to have not expanded radially inward from the stent 120 and thus will not interfere with the blood flow through the valve 100 .
- the adaptive seal 130 comprises a hydrogel material.
- the hydrogel can be provided as a colloidal gel, such as a hydrocolloid, a coating, a film, or a foam, or it can be provided on a substrate, such as on a cloth or about a shape memory metal or metal coil. While the embodiments depicted in FIGS. 1A and 1B depict the adaptive seal 130 as a strip of material that is affixed to the outer periphery of the stent 120 , it is understood that the stent 120 can be directly coated with a hydrogel material. Thus, in one preferred embodiment, the stent 120 is coated or dipped in a hydrogel solution, then allowed to dry before it is coupled to the biological tissue to form a heart valve.
- the adaptive seal 130 comprises a substrate and an expandable material, such as hydrogels, such as zwitterionic hydrogels, SAPs, elastomeric materials or other swellable or absorbent polymer or elastomeric material disposed on the substrate.
- the substrate can be an impermeable material, such as a film (e.g., a MYLAR® polyester film), or it can be permeable material, such as a densely-woven cloth.
- the substrate is expandable, elastically or otherwise, such that it can be wrapped around the external periphery of the heart valve in a collapsed state and expand as the heart valve is deployed to an expanded state.
- the hydrogel material is disposed on an inelastic material, such as a metal film or coil
- the inelastic material assumes a particular geometry (e.g., folded, coiled, etc.) that permits expansion.
- the substrate is preferably positioned outwardly of the stent 120 and between the stent 120 and the hydrogel material.
- the main function of the substrate is to prevent the hydrogel material from expanding radially inward and thus to limit the expansion of the hydrogel material in a radially outward direction along B2-B2 as depicted in FIG. 2B .
- the densely-woven cloth when stretched around the circumference of a fully-expanded valve, does not permit the hydrogel material to migrate through the cloth and into the internal lumen of the stent 120 .
- the adaptive seal 130 preferably expands only radially outwardly of the heart valve 100 .
- a hydrogel is generally understood to refer to a polymer or other material that expands or swells in response to an initiating condition, such as changes in temperature, electrical field, magnetic field, chemical environment, pH, and/or phase changes, for example, contact with a liquid.
- the adaptive seal does not comprise, or is not, a silicone polymer or other lubricous material.
- One type of hydrogel is a hydrophilic polymer which physically expands or swells when it contacts and absorbs a liquid, such as water.
- the extent of the physical expansion or swelling by a hydrophilic polymer is typically limited by the covalent or physical cross-links that oppose the absorption of water once the hydrogel reaches an equilibrium swelling state. Thus, the extent of expansion may be designed or tuned to preferred dimensions based on chemically modifying these crosslinkages.
- Hydrophilic polymers are highly absorbent and possess a degree of flexibility that is very similar to natural tissue due to their substantial water content.
- hydrophilic polymers include, but are not limited to, poly(ethylene oxide), poly(hydroxyethyl methacrylate), poly(vinyl alcohol), polyacrylamide, poly(vinylpyrrolidone), poly(ethyloxazoline), poly(propylene oxide), poly(ethylene glycol)poloxamines, polyacrylamide, hydroxypropylmethacrylate (HPMA), poly(ethylene glycol), polymethacrylate, poly(methyl methacrylate)polylactic acid, carboxymethyl cellulose, hydroxyethyl cellulose, methylhydroxypropyl cellulose, polysucrose, hyaluronate, chondroitin sulfate, dextran, alginate, chitosan, gelatin, and derivatives, mixtures, and copolymers thereof.
- Hydrogels can be sensitive to stimuli and respond to changes in the surrounding environment, e.g., an initiating condition, such as changes in temperature, electrical field, magnetic field, chemical environment, pH, and/or phase changes, for example, contact with a liquid.
- an initiating condition such as changes in temperature, electrical field, magnetic field, chemical environment, pH, and/or phase changes, for example, contact with a liquid.
- the hydrogels contemplated for use in connection with bioprosthetic heart valves, as described herein, are initially provided in the contracted state and expand or swell only after exposure to an initiating condition.
- the rate and extent of swelling of the hydrogel can be configured by chemically modifying the hydrogel.
- the hydrogel can be crosslinked with cross-linkers that degrade in response to being exposed to the same or a different initiating condition that causes the hydrogel to expand or swell.
- the rate and extent of expansion of the hydrogel is controlled and fine-tuned by chemically modifying the hydrogel or by incorporating degradable cross-linkers.
- the adaptive seal is or comprises a delayed-swelling hydrogel which will not expand for a period of time after exposure to an initiating condition. This period of time is preferably at least 1 minute, more preferably at least 2 minutes, and most preferably at least 5 minutes.
- the delayed-swelling hydrogel can be produced by incorporating biodegradable cross-linkers in the hydrogel polymer to generate a delayed swelling hydrogel.
- the biodegradable cross-linkers can degrade at a desired rate to permit swelling at a corresponding rate after an initial exposure to the initiating condition.
- the cross-linkers can be selected to slowly degrade upon exposure to a physiological fluid, such as blood. As the cross-linkers degrade, the hydrogel will expand and swell.
- the hydrogel preferably reaches its full expansion, e.g., an equilibrium state, within a period of time to permit the implanting physician to confirm the absence of PVL of the implanted heart valve.
- the adaptive seal reaches its full expansion within 5 hours of implantation, preferably within 1 hour of implantation, and most preferably within 15 minutes of implantation.
- the biodegradable cross-linkers of the hydrogel are preferably completely degraded or severed within 5 hours, preferably within 1 hour, and most preferably within 15 minutes of exposure to the initiating condition.
- FIGS. 3A and 3B depict a surgical heart valve 200 comprising a biological tissue leaflet structure 210 comprising three flexible leaflets and a frame 220 comprising three commissure posts.
- a sewing ring 225 defines the inflow portion of the valve 200 and is used to attach the valve 200 to the valve annulus.
- the sewing ring 225 can be circular or scalloped.
- the sewing ring 225 defines a suture-permeable cuff made of an inner body of silicone covered with a permeable or semi-permeable material or fabric.
- the adaptive seal 230 is preferably a hydrogel which is exposed and coupled externally about the circumferential edge of the sewing ring 225 to provide conforming engagement between the sewing ring 225 and the inner surface of the annulus where the valve is implanted (not shown).
- the adaptive seal 230 can also be provided inside the sewing ring 225 , with a permeable or semi-permeable fabric covering being made of a material having sufficient elasticity to permit swelling and expansion of the adaptive seal 230 within the sewing ring 225 .
- the adaptive seal 230 can also be provided as a hydrogel coating on the sewing ring 225 as a result of dipping the material or fabric constituting the sewing ring into a hydrogel solution.
- the adaptive seal 230 comprises a hydrogel material that is disposed on a wire that is wrapped around the sewing ring 225 and preferably secured onto the sewing ring by adhesives or by sutures. Because the valve 200 is surgically implanted and does not require the valve 200 to be crimped or collapsed, the substrate for the hydrogel material is not required to be expandable or elastic.
- FIGS. 4A and 4B depict an embodiment of a transcatheter heart valve 300 which comprises an adaptive seal 330 a of a different configuration from the one depicted in FIGS. 1-2 .
- the heart valve 300 comprises a biological tissue leaflet 310 attached to a stent 320 .
- the heart valve 300 is further depicted as comprising a hydrogel-coated wire 330 a surrounding the periphery of the stent 320 .
- the hydrogel-coated wire 330 a by virtue of its geometry, comprising a plurality of loops, will permit expansion of the heart valve 300 for implantation.
- One or more hydro-gel coated wires can be used on the valve.
- the hydrogel-coated wire 330 a is formed as a plurality of loops.
- the hydrogel-coated wire 330 a comprises a plurality of larger loops.
- the loops reduce in size significantly. The presence of the loops provides a degree of flexibility for radial expansion of the heart valve 300 .
- Suitable hydrogel-coated wires include Azur Peripheral HYDROCOIL® (MicroVention Terumo, Inc., Aliso Viejo, Calif.), which is a platinum coil with an expandable poly(acrylamide-co-acrylic acid) hydrogel and overcoiled with a stretched platinum coil.
- An advantage of using the hydrogel-coated wire 330 a is that it stays substantially close to the stent 320 in both the expanded and the compressed states such that it does not significantly add material bulk. This permits the fabrication of transcatheter heart valves having substantially narrower delivery profiles than would be expected when such valves include a PVL skirt, for example.
- the hydrogel-coated wires is attached to the stent 320 by crimping.
- the hydrogel-coated wires are crimped in one, two, three, or four locations along the stent 320 .
- the hydrogel-coated wire 330 a is positioned around the entire circumference of the heart valve at a distance from both the inflow end 302 and the outflow end 304 .
- the hydrogel-coated wire 330 a undergoes limited expansion within the first 3 minutes, and fully expands within 20 minutes.
- FIGS. 4A and 4B depict the adaptive seal 330 a taking the form of a hydrogel-coated wire, it is understood that the adaptive seal 330 a can also be provided as a hydrogel coating on the stent 320 .
- the stent 320 can be dipped in or spray coated with a hydrogel solution and allowed to dry prior to assembling the stent 320 with the tissue leaflet 310 .
- FIGS. 4C and 4D depict the heart valve 300 in which the hydrogel-coated wire 330 b is provided in two different configurations.
- the hydrogel-coated wire 330 b is provided in a first configuration, in which the hydrogel-coated wire 330 b is tightly coiled.
- the hydrogel-coated wire 330 b is provided in a second configuration, in which the hydrogel-coated wire 330 b is substantially straight.
- the hydrogel-coated wire 330 b can comprise a shape memory metal, such as Nitinol, such that it takes on the substantially straight configuration upon being heated to a particular temperature, preferably in the range of about 24-37° C.
- a shape memory metal such as Nitinol
- the temperature at which a shape memory metal, such as Nitinol, will change configurations can be fine-tuned by altering the profile of the shape memory metal.
- the hydrogel-coated wire 330 b can be a non-metal wire that is elastically stretchable between the first and second configurations. It is understood that where an elastic wire is used, the elastic wire does not cause significant compression of the stent 320 in an expanded state.
- FIGS. 4E and 4F depict the heart valve 300 in which the hydrogel-coated wire 330 c is provided as a straight wire that encircles or is coiled around the outer external periphery of the heart valve 300 .
- the hydrogel-coated wire 330 c has a length that permits it to be coiled around the entire outer circumference of the compressed valve ( FIG. 4E ) more than once.
- the other free end of the hydrogel-coated wire 330 c is permitted to move in relation to the valve 300 as it is expanded to the fully-expanded state ( FIG. 4F ).
- the hydrogel-coated wire 330 c has a length that permits it to be coiled around the heart valve in its fully-expanded state at least once, if not twice.
- One advantage provided by the hydrogel-coated wire 330 c in FIGS. 4E-4F is that it will add, to a lesser event, to the delivery profile of the compressed heart valve 300 .
- FIGS. 5A and 5B depict an embodiment of a replacement heart valve 400 which can be implanted using minimally-invasive techniques.
- the heart valve 400 comprises a biological tissue 410 coupled to a supporting frame 420 comprising three commissure posts, a sewing ring 425 and a frame stent 430 comprising a cloth covered anchoring frame.
- the frame stent 430 can be balloon expanded after implantation and is characterized as providing a greater area of engagement between the heart valve 400 and the arterial or cardiac walls. The frame stent 430 therefore is believed to reduce the incidence of PVL of the implanted heart valve 400 .
- the frame stent 430 or the cloth material constituting the frame stent 430 can be coated with the adaptive seal or hydrogel material.
- the adaptive seal or hydrogel material can be contained within the cloth material of the frame stent 430 .
- the replacement heart valve 400 is that the manufacturing of the valve portion consisting of the biological tissue 410 , the supporting frame 420 and the sewing ring 425 can be done separately from the manufacture of the cloth-covered frame stent 430 to constitute the adaptive seal.
- the cloth covered frame stent 430 is dipped in or sprayed with a hydrogel solution prior to assembly with the valve portion.
- the hydrogel material can be provided within the cloth covered frame stent 430 , provided that the cloth is sufficiently elastic to permit expansion by the hydrogel material contained therein.
- FIGS. 6A-6C depict an expandable bioprosthetic heart valve 600 and its delivery system 602 in the various stages from a collapsed delivery configuration with the adaptive seal 610 being adjacent the delivery system, as depicted in FIG. 6A , an intermediate configuration with the adaptive seal 610 is positioned around the bioprosthetic heart valve 600 , as depicted in FIG. 6B , and an expanded configuration, in which the heart valve 600 is fully expanded and the adaptive seal 610 being disposed around the heart valve 600 , as depicted in FIG. 6C .
- the adaptive seal 610 depicted in FIGS. 6A through 6C is a hydrogel-coated wire.
- Expandable bioprosthetic heart valves are known in the art and the illustrated heart valve 600 illustrated in FIGS. 6A through 6C is representative of a number of such valves which can be converted from a narrow constructed configuration to a wider expanded configuration.
- the valves are balloon expanded into position at a target annulus after having been advanced through the vasculature, although self-expanding valves are also known.
- the most common delivery routes commence at the femoral or carotid arteries, though other more direct routes through chest ports are also known.
- One such expandable prosthetic heart valve is the Edwards SAPIEN® or SAPIEN XT® Transcatheter Heart Valve available from Edwards Lifesciences of Irvine, Calif.
- the Edwards SAPIEN® valve can be placed either through a transfemoral or transapical approach.
- the delivery system 602 includes an elongated catheter 604 having an expansion balloon 646 near a distal end thereof.
- the bioprosthetic heart valve 600 mounts around the balloon 646 and is expanded thereby.
- the system further includes proximal connectors 608 for delivery of balloon inflation fluid, passage of a guide wire, or other such functions.
- the bioprosthetic heart valve 600 includes a plurality of balloon expandable struts in between three axially-oriented commissure bars 605 .
- Bioprosthetic tissue mounts within the framework created by the struts and bars 605 , such as with supplementary fabric.
- the delivery profile of the collapsed delivery configuration As depicted in FIG. 6A .
- One way of achieving a reduced delivery profile is to provide the adaptive seal 610 such that it does not initially encircle or wrap the collapsed bioprosthetic heart valve 600 but instead is allowed to trail along the elongated catheter in a first delivery configuration.
- the collapsed delivery configuration depicted in FIG. 6A is provided within a sheath (not shown). Reducing the delivery profile of the collapsed delivery configuration will permit a reduced French size for the corresponding sheath.
- both the bioprosthetic heart valve 600 and the adaptive seal 610 will be exposed to blood and other bodily fluids.
- the adaptive seal 610 it is undesirable for the adaptive seal 610 to swell or expand substantially, if at all, immediately upon exposure to blood because such expansion will interfere with the ability to deliver the bioprosthetic heart valve 600 through the patient's vasculature and to advance the valve 600 out of the delivery sheath.
- the adaptive seal 610 is chemically tuned such that it will respond to one or a plurality of initiating conditions, such as, for example, exposure to liquid and an additional condition, such as pH, temperature, a change in the electrical or magnetic field, or a change in the chemical environment, after a predetermined period of time of such exposure.
- the adaptive seal 610 will include a biodegradable cross-linker which degrades at a predetermined rate upon exposure to an initiating condition.
- the sheath is removed.
- the adaptive seal 610 coils or wraps around the external periphery of the heart valve 600 in a second configuration.
- the adaptive seal 610 can be comprised of a hydrogel material disposed on either a shape memory metal or other material that is configured to elastically wrap around the heart valve 600 once it is exposed from the sheath.
- the length of the adaptive seal 610 is longer than the circumference of the fully-expanded valve 600 such that a portion of the adaptive seal 610 overlaps. In this manner, gaps between the two ends of the adaptive seal 610 can be avoided.
- the adaptive seal 610 preferably comprises a shape-memory material or metal, such as Nitinol, which is coated with a hydrogel and which is configured to coil around the outer circumference of the valve 600 based reaching or exceeding a transformation temperature.
- the transformation temperature is between about 24-25° C., about 25-26° C., about 26-27° C., about 27-28° C., about 28-29° C., about 29-30° C., about 30-31° C., about 31-32° C., about 32-33° C., about 33-34° C., about 34-35° C., about 35-36° C., and about 36-37° C.
- the transformation temperature for the stent is higher than the transformation temperature for the adaptive seal 610 so as to ensure that the adaptive seal 610 coils around the valve 600 before the valve 600 begins to expand or is substantially or fully expanded.
- FIG. 6C depicts the bioprosthetic heart valve 600 in a fully-expanded configuration with the adaptive seal 610 being disposed around the circumference of the valve 600 .
- the adaptive seal 610 does not swell or expand until after it assumes a fully expanded configuration as depicted in FIG. 6C .
- FIGS. 7A-7C depict the expandable bioprosthetic heart valve 600 having a hydrogel-coated wire 610 a taking on different configurations that similarly permit a smaller delivery profile.
- the hydrogel-coated wire 610 a is provided in a first delivery configuration as a straight wire, as depicted in FIG. 7A . This permits the compressed bioprosthetic heart valve 600 and its delivery system 602 to fit within a sheath having a reduced delivery profile.
- the hydrogel-coated wire 610 a takes on a second configuration, in which it is both coiled and wrapped around the outer periphery of the heart valve 600 at least two times ( FIG. 7B ), and a third configuration, in which the hydrogel-coated wire 610 a remains in a coiled configuration but is wrapped around the outer periphery of the heart valve 600 only once ( FIG. 7C ).
- FIGS. 8A-8C depict the expandable bioprosthetic heart valve 600 having a hydrogel-coated wire 610 b taking on another alternate configuration permitting a smaller delivery profile.
- the hydrogel-coated wire 610 b is provided in a first delivery configuration as a straight wire, as depicted in FIG. 8A . This permits the compressed bioprosthetic heart valve 600 and its delivery system 602 to fit within a sheath having a reduced delivery profile. Once the sheath (not shown) is removed, the hydrogel-coated wire 610 b takes on a second configuration, in which it is wrapped around the outer periphery of the heart valve 600 ( FIGS. 8B and 8C ).
- the length of the hydrogel-coated wire 610 b is provided such that it encircles the external periphery of the compressed valve a plurality of times, preferably at least 2, 3, or 4 times ( FIG. 8B ).
- the heart valve 600 is permitted to expand radially in its fully expanded state ( FIG. 8C ).
- the heart valve 600 can be packaged in a collapsed delivery configuration with the adaptive seal being positioned adjacent the delivery system 602 as depicted in FIG. 6A , 7 A or 8 A. This allows the heart valve 600 to be provided to the implanting physician in a substantially ready-to-use condition out of the package.
- the biological tissues suitable for the heart valves described herein are treated so as to permit storage without a liquid preservative solution, e.g., dry storage.
- the biological tissue can be contacted or immersed in a treatment solution comprising a polyhydric alcohol or polyol, preferably a glycerol.
- the glycerol can be provided in an aqueous, non-aqueous or a substantially non-aqueous solution.
- the non-aqueous solution (the solvent is not water) or the substantially non-aqueous solution is an alcoholic solution.
- the alcoholic solution comprises one or a combination of lower alcohols, preferably C 1 -C 3 alcohols.
- the biological tissue following treatment with the treatment solution is dehydrated or substantially dehydrated.
- the water content of the biological tissue following treatment with the treatment solution is reduced at least about 10%, preferably at least about 25%, preferably at least about 50%, preferably at least about 75%, preferably at least about 80%, and preferably at least about 90%.
- the time of contact between the biological tissue and the treatment solution depends on the thickness and type of tissue.
- the tissue is removed from the solution and exposed to ambient air or an inert environment (e.g., nitrogen), at standard room temperature and humidity so as not to adversely affect tissue properties.
- the drying is performed in a clean room or in a laminar flow bench at ambient room conditions for about 1 to 4 hours.
- the treatment solution is a solution of glycerol and a C 1 -C 3 alcohol, wherein the treatment solution comprises about 60-95% by volume glycerol. Suitable treatment for the biological tissues are described in U.S. Pat. No. 8,007,992, issued Aug.
- the tissue can be treated as described in U.S. Pat. No. 6,534,004, issued Mar. 18, 2003, issued to The Cleveland Clinic Foundation, the entire contents of which are incorporated herein by reference in its entirety as if fully set forth herein.
- the adaptive seal is made of a material that expands after exposure to one or more initiating conditions.
- the adaptive seal is preferably a hydrophilic polymer or a hydrogel-coated wire that is made up of a hydrogel material that expands or swells when exposed to an aqueous liquid, such as saline or blood.
- the hydrogel material does not fully expand or swell until after a period of contact with the initiating condition (e.g., fluid), which provides physicians the ability to deliver and control the implantation of the device at the desired location. This can be accomplished by utilizing hydrogels or hydrogel-coated wires in which the hydrogel material has been cross-linked with a degradable cross-linker.
- the substantial expansion of the adaptive seal takes place after initial contact with the initiating condition.
- the seal can be made of a hydrogel that initially expands slowly and then expands more rapidly after a period of time has elapsed from exposure to the initiating condition.
- the rapid expansion of the adaptive seal occurs about 30 seconds, about 60 seconds, about 2 minutes, or about 5 minutes after exposure to the initiating condition.
- the adaptive seal is provided in a substantially dehydrated state.
- the adaptive seal described herein can be provided in the form of a cloth, a film, a coating, a foam, or a hydrogel-coated wire and comprise an expandable material that impregnates a suitable substrate, is chemically coupled to a suitable substrate, or is contained within a permeable or semi-permeable barrier that permits the entry of fluid but contains the expandable material.
- the expandable material is preferably a hydrogel or an organic polymer that is cross-linked via covalent, ionic or hydrogen bonds to create a three-dimensional open lattice structure which entraps water molecules to form a gel.
- the adaptive seal is a hydrogel-coated wire, such as HYDROCOIL® (MicroVention Terumo, Inc., Aliso Viejo, Calif.), which is a platinum coil with an expandable poly(acrylamide-co-acrylic acid) hydrogel and overcoiled with a stretched platinum coil.
- HYDROCOIL® MicroVention Terumo, Inc., Aliso Viejo, Calif.
- the adaptive seal expands from its reduced radial profile to an increased radial profile.
- the bioprosthetic heart valve and adaptive seal can preferably be packaged in double sterile barrier packaging consisting of a rigid tray (PETG) with a TYVEK® non-woven polyolefin lid. The package is sealed in a cleanroom and sterilized in 100% ethylene oxide.
- Suitable packaging systems for the bioprosthetic heart valves disclosed herein are described in U.S. Patent Application Publication No. 2011/0214398, published Sep. 8, 2011, to Edwards Lifesciences Corp., and is incorporated herein by reference in its entirety.
- suitable packaging systems are described in U.S. Patent Application Publication No. 2013/0152659, published Jun. 20, 2013; U.S. Patent Application Publication No. 2012/0158128, Jun. 21, 2012, and U.S. Patent Application Publication No. 2012/0239142, published Sep. 20, 2012, all to Edwards Lifesciences Corp, and all incorporated by reference herein in their entireties.
Abstract
A packaged bioprosthetic heart valve comprising a bioprosthetic heart valve, an adaptive seal and a package. The bioprosthetic heart valve comprises an at least partially dehydrated biological tissue leaflet structure coupled to a supporting frame. The bioprosthetic heart valve has a periphery, an inflow portion, and an outflow portion. The adaptive seal is coupled to the bioprosthetic heart valve around at least a portion of the periphery. The adaptive seal comprises an expandable material that expands after exposure to an initiating condition. The bioprosthetic heart valve and the adaptive seal is stored and contained within the package, which does not contain a liquid storage solution in contact with the bioprosthetic heart valve and the adaptive seal.
Description
- This application claims the benefit of U.S. Patent Application No. 61/900,827, filed Nov. 6, 2013, the entire disclosure of which is incorporated by reference.
- The invention relates to a heart valve prosthesis and, more particularly, to a heart valve prosthesis having an adaptive seal that minimizes perivalvular leakage following implantation.
- Perivalvular leakage (PVL) is a complication that is related to the replacement of heart valves. It occurs when blood flows through a channel or gap between the structure of an implanted valve and the cardiac or arterial tissue due to a lack of appropriate sealing.
- Intimate apposition of replacement heart valves and the surrounding cardiac or arterial walls seals the valve and minimizes PVL. In certain cases, however, a seal cannot be achieved, leaving irregular gaps of different sizes and shapes between the valve and the cardiac or arterial walls. This may result from inadequate sizing, incomplete expansion of the valve, an irregularly deformed valve, or highly eccentric or irregular calcification pattern on the leaflets or valve annulus.
- PVL has been shown to greatly affect the clinical outcome of transcatheter aortic valve replacement procedures, and the severity of perivalvular leakage has been correlated with patient mortality. What is therefore needed is a replacement bioprosthetic heart valve which permits a conforming engagement or fit with the surrounding cardiac or arterial wall so as to substantially fill in the gaps or channels that often result in PVL.
- Bioprosthetic heart valves having the adaptive seals described herein are preferably valves which comprise a biological tissue that has been treated so as to not require storage in liquid preservative solutions. While mechanical heart valves are capable of being stored in a dry state, valves having biological tissue typically require storage in liquid preservative solutions. Storage in liquid preservative solutions introduces a host of challenges for valves which include adaptive seals, particularly for those which are activated to expand upon exposure to liquid.
- Significant advantages are provided by the bioprosthetic heart valves disclosed herein, in which the biological tissue is treated so as to permit dry storage of the valves without a liquid storage solution. The adaptive seals can be exposed on the heart valve without requiring encapsulation or a barrier from the environment, as would be required if the valves were to be stored in a liquid preservation solution. To that end, the adaptive seals can simply comprise the expandable material exposed or contained within a permeable or semi-permeable material that permits fluid to come into contact with the expandable material, while supporting or containing the expandable material. In a preferred embodiment, the replacement heart valve or the adaptive seal is not selectively encapsulated by a non-permeable barrier.
- The simplicity of being able to provide an adaptive seal structure, without selective encapsulation, provides significant advantages over prior art heart valves in which the selective encapsulation of the adaptive seal in a liquid storage solution is a necessity. The selective encapsulation methods of the prior art are required to permit the tissue portion of the valve to be in contact with the liquid storage solution while at the same time segregating the adaptive seal portion from the liquid storage solution. If the adaptive seal is not selectively encapsulated from the liquid storage solution, it will expand and render the heart valve unusable.
- The bioprosthetic heart valves contemplated within this disclosure can be any implantable heart valve which preferably comprises a biological tissue. Such valves include transcatheter valves, surgical valves, minimally-invasive valves, and the like. The biological tissue can be derived from animal sources, preferably, from pericardial tissue, and most preferably, from bovine pericardial tissue. The biological tissue is used to form the leaflets of the heart valve and is mounted to a supporting frame or stent to form a bioprosthetic heart valve. Because the valves are stored dry, the biological tissues are treated so as to preserve their pliability and flexibility in a dry state, e.g., without storage in a liquid storage solution.
- The terms “dry” or “dehydrated”, as used herein, are understood to include residual moisture or humidity from the ambient environment and is intended to mean that the valves are not immersed in, or in contact with, a liquid or a storage solution.
- In one embodiment, a method for manufacturing a bioprosthetic heart valve is described. The method comprises providing a bioprosthetic heart valve comprising a biological tissue that has been treated with a treatment solution comprising a polyhydric alcohol, the bioprosthetic heart valve having a periphery, an inflow portion and an outflow portion. The method further comprises coupling an adaptive seal to the bioprosthetic heart valve, the adaptive seal comprising an expandable material that expands after exposure to an initiating condition. The method further comprises packaging the bioprosthetic heart valve and the coupled adaptive seal in a package that does not contain a liquid storage solution in contact with the bioprosthetic heart valve and the coupled adaptive seal. In a preferred embodiment, the adaptive seal is not further encapsulated, segregated or enclosed from the biological tissue.
- In accordance with a first aspect of the embodiment, the polyhydric alcohol is glycerol.
- In accordance with a second aspect of the embodiment, the biological tissue is at least partially dehydrated following treatment with the treatment solution.
- In accordance with a third aspect of the embodiment, the adaptive seal is a hydrophilic polymer or a hydrogel-coated wire.
- In accordance with a fourth aspect of the embodiment, the hydrophilic polymer or the hydrogel-coated wire comprises a biodegradable cross-linker. Expansion of the adaptive seal is delayed for a period of time after exposure to the initiating condition.
- In accordance with a fifth aspect of the embodiment, the initiating condition is one or more selected from the group consisting of: a change in temperature, a change in the electrical field, a change in the magnetic field, a change in the chemical environment, a change in pH, and contact with a liquid.
- In accordance with a sixth aspect of the embodiment, the expandable material expands longitudinally, radially, or both longitudinally and radially relative to the bioprosthetic heart valve after exposure to the initiating condition.
- In accordance with a seventh aspect of the embodiment, the bioprosthetic heart valve comprises a stent and the coupling comprises coating the stent with the adaptive seal or coupling patches within open cells defined by the stent.
- In another embodiment, a packaged bioprosthetic heart valve is provided. The packaged bioprosthetic heart valve comprises a bioprosthetic heart valve, an adaptive seal coupled to the bioprosthetic heart valve, and a sealed package containing the bioprosthetic heart valve and the adaptive seal. The bioprosthetic heart valve comprises a dehydrated biological tissue leaflet structure coupled to a supporting frame, the bioprosthetic heart valve having a periphery, an inflow portion, and an outflow portion. The adaptive seal comprises an expandable material that expands after exposure to an initiating condition. The sealed package containing the bioprosthetic heart valve and the adaptive seal does not contain a liquid storage solution in contact with the bioprosthetic heart valve and the adaptive seal.
- In accordance with a first aspect of the embodiment, the adaptive seal is a hydrophilic polymer or a hydrogel-coated wire.
- In accordance with a second aspect of the embodiment, the adaptive seal is a hydrogel comprising a biodegradable cross-linker and expansion of the adaptive seal is delayed for a period of time after exposure to the initiating condition.
- In accordance with a third aspect of the embodiment, the adaptive seal is a hydrogel-coated wire comprising a shape memory metal, the hydrogel-coated wire changing from a first configuration to a second configuration upon reaching or exceeding a transformation temperature.
- In accordance with a fourth aspect of the embodiment, in the first configuration, the hydrogel-coated wire has one of a straight or a coiled configuration and in the second configuration, the hydrogel-coated wire has the other of the straight or coiled configuration.
- In accordance with a fifth aspect of the embodiment, the adaptive seal is coupled to the bioprosthetic heart valve at a spaced distance from both of the inflow and outflow portions.
- In accordance with a sixth aspect of the embodiment, the adaptive seal is provided circumferentially about the bioprosthetic heart valve.
- In accordance with a seventh aspect of the embodiment, the bioprosthetic heart valve further comprises a sewing ring and the adaptive seal is coupled to and exposed from the sewing ring or contained within the sewing ring.
- In accordance with an eighth aspect of the embodiment, the supporting frame is a stent comprising a plurality of struts and open cells.
- In accordance with a ninth aspect of the embodiment, the adaptive seal is coupled to one or more struts of the supporting frame.
- In accordance with a tenth aspect of the embodiment, the adaptive seal forms one of a coating on at least a portion of the stent.
- In accordance with an eleventh aspect of the embodiment, the adaptive seal is provided as patches disposed within the open cells defined by the stent.
- Other objects, features and advantages of the described preferred embodiments will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.
- Illustrative embodiments of the present disclosure are described herein with reference to the accompanying drawings, in which:
-
FIG. 1A is a side view of an embodiment of an implanted bioprosthetic heart valve with an adaptive seal in a substantially unexpanded state. The arterial walls are cut away to show the gaps between the implanted bioprosthetic heart valve and the arterial walls. -
FIG. 1B is a plan view of the outflow portion of the implanted bioprosthetic heart valve ofFIG. 1A showing the adaptive seal in a substantially unexpanded state within the arterial walls. -
FIG. 2A is a side view of the implanted bioprosthetic heart valve with the adaptive seal in a substantially expanded state. The arterial walls are cut away to show the adaptive seal expanded to fill at least some of the gaps between the implanted bioprosthetic heart valve and the arterial wall. -
FIG. 2B is a plan view of the outflow portion of the implanted bioprosthetic heart valve showing the adaptive seal in a substantially expanded state, with the arterial walls cut away to reveal the implanted bioprosthetic heart valve. -
FIG. 3A is a perspective view of the outflow portion of another embodiment of a bioprosthetic heart valve with the adaptive seal located about the periphery of the sewing ring. -
FIG. 3B is a perspective view of the inflow portion of the bioprosthetic heart valve ofFIG. 3A . -
FIGS. 4A-4B are perspective views of an embodiment of a bioprosthetic heart valve in a collapsed and an expanded state, respectively. -
FIGS. 4C-4D are perspective views of another embodiment of a bioprosthetic heart valve in a collapsed and an expanded state, respectively. -
FIGS. 4E-4F are perspective views of a further embodiment of a bioprosthetic heart valve in a collapsed and an expanded state, respectively. -
FIG. 5A is an exploded perspective view of a further embodiment of a bioprosthetic heart valve showing the tissue valve portion and the stented sealing cloth. -
FIG. 5B is a perspective view of the bioprosthetic heart valve ofFIG. 5A in which the tissue valve portion and the stented sealing cloth are assembled together. -
FIGS. 6A-6C are broken plan views of an embodiment of an expandable bioprosthetic heart valve and its delivery system in the various stages from a collapsed delivery configuration with the adaptive seal being adjacent the delivery system (FIG. 6A ), an intermediate configuration with the adaptive seal is positioned around the bioprosthetic heart valve (FIG. 6B ) and an expanded configuration, ready for full expansion of the adaptive seal (FIG. 6C ). -
FIGS. 7A-7C are broken plan views of another embodiment of an expandable bioprosthetic heart valve and its delivery system in the various stages from a collapsed delivery configuration with the adaptive seal being adjacent the delivery system (FIG. 7A ), an intermediate configuration with the adaptive seal is positioned around the bioprosthetic heart valve (FIG. 7B ) and an expanded configuration, ready for full expansion of the adaptive seal (FIG. 7C ). -
FIGS. 8A-8C are broken plan views of an expandable bioprosthetic heart valve and its delivery system in the various stages from a collapsed delivery configuration with the adaptive seal being adjacent the delivery system (FIG. 8A ), an intermediate configuration with the adaptive seal is positioned around the bioprosthetic heart valve (FIG. 8B ) and an expanded configuration, ready for full expansion of the adaptive seal (FIG. 8C ). - Like numerals refer to like parts throughout the several views of the drawings.
- Specific, non-limiting embodiments of the present invention will now be described with reference to the drawings. It should be understood that such embodiments are by way of example only and merely illustrative of but a small number of embodiments within the scope of the present invention. Various changes and modifications obvious to one skilled in the art to which the present invention pertains are deemed to be within the spirit, scope and contemplation of the present invention as further defined in the appended claims.
-
FIGS. 1A and 1B depict atranscatheter heart valve 100 that has been expanded and implanted within anarterial wall 1. Thetranscatheter heart valve 100 generally comprises a biologicaltissue leaflet structure 110 that is coupled to an expandable frame orstent 120. It is understood that thestent 120 can either be self-expanding or balloon-expandable. Theheart valve 100 further comprises aninflow portion 102, anoutflow portion 104 and askirt 125 that is coupled to thestent 120, preferably by sutures, and located proximate theinflow portion 102. - The external peripheral surface of the
heart valve 100 is shown to be in discontinuous engagement with the inner surface of thearterial wall 1 as shown by the gaps orvoids 2 between them. These gaps result because the inner surface of thearterial wall 1 is typically an irregular surface. To provide a conforming fit or engagement between theheart valve 100 and the inner surface of thearterial wall 1, anadaptive seal 130 is provided around the external peripheral surface of theheart valve 100. Theadaptive seal 130 preferably comprises an expandable or swellable material, such as hydrogels (e.g., zwitterionic hydrogels), super absorbent polymers (SAPs), elastomeric materials or other swellable or absorbent polymer or elastomeric materials. Preferably, theadaptive seal 130 does not comprise silicone or other lubricious materials or polymers that would potentially cause the implantedvalve 100 to slip or dislodge from its initial site of implantation. - The
adaptive seal 130 can be coupled to the outer periphery of thestent 120, as shown inFIGS. 1A and 1B , by adhesives or by one or more sutures. As can be seen inFIGS. 1-2 , thestent 120 further defines a plurality of open spaces or cells. Thus, theadaptive seal 130 can also be provided as a plurality of discrete patches that can be disposed within selected ones of the plurality of open spaces or cells defined by thestent 120. - As shown in
FIGS. 1A and 1B , theadaptive seal 130 has a substantially unexpanded length (A1-A1,FIG. 1A ) and a substantially unexpanded radial thickness (B1-B1,FIG. 1B ) upon initial implantation. Because theadaptive seal 130 will expand both along its length and radial thickness, it is preferably positioned around theheart valve 100 at a sufficient distance away from both theinflow portion 102 andoutflow portion 104 such that the fully expandedadaptive seal 130 does not extend beyond thestent 120. In addition, theadaptive seal 130 is constructed such that inward radial expansion into the lumen of the heart valve is limited, if not prevented. Thus, expansion of theadaptive seal 130 is preferably limited to the area between the outer periphery of thestent 120 and thearterial wall 1. -
FIGS. 2A and 2B depict thetranscatheter heart valve 100 ofFIGS. 1A and 1B in which theadaptive seal 130 has expanded after exposure to an initiating condition. Expansion of theadaptive seal 130 takes place in a conforming, non-rigid manner and theadaptive seal 130 preferably expands in directions of least resistance, e.g., into the spaces orgaps 2 between thestent 120 and thearterial wall 1. In other words, the expansion of theadaptive seal 130 takes place to a greater degree in areas where there are larger gaps between thestent 120 and thearterial wall 1 and to a lesser degree in areas where thegaps 2 are smaller. Theadaptive seal 130 preferably expands along one or both of its longitudinal length (A2-A2,FIG. 2A ) and its radial thickness (B2-B2,FIG. 2B ). In the embodiment depicted herein, theadaptive seal 130 is shown to have not expanded radially inward from thestent 120 and thus will not interfere with the blood flow through thevalve 100. - In a preferred embodiment, the
adaptive seal 130 comprises a hydrogel material. The hydrogel can be provided as a colloidal gel, such as a hydrocolloid, a coating, a film, or a foam, or it can be provided on a substrate, such as on a cloth or about a shape memory metal or metal coil. While the embodiments depicted inFIGS. 1A and 1B depict theadaptive seal 130 as a strip of material that is affixed to the outer periphery of thestent 120, it is understood that thestent 120 can be directly coated with a hydrogel material. Thus, in one preferred embodiment, thestent 120 is coated or dipped in a hydrogel solution, then allowed to dry before it is coupled to the biological tissue to form a heart valve. - In a preferred embodiment, the
adaptive seal 130 comprises a substrate and an expandable material, such as hydrogels, such as zwitterionic hydrogels, SAPs, elastomeric materials or other swellable or absorbent polymer or elastomeric material disposed on the substrate. The substrate can be an impermeable material, such as a film (e.g., a MYLAR® polyester film), or it can be permeable material, such as a densely-woven cloth. In either case, the substrate is expandable, elastically or otherwise, such that it can be wrapped around the external periphery of the heart valve in a collapsed state and expand as the heart valve is deployed to an expanded state. In embodiments where the hydrogel material is disposed on an inelastic material, such as a metal film or coil, the inelastic material assumes a particular geometry (e.g., folded, coiled, etc.) that permits expansion. - Additionally, the substrate is preferably positioned outwardly of the
stent 120 and between thestent 120 and the hydrogel material. In the embodiment depicted inFIGS. 1A-1B and 2A-2B, the main function of the substrate is to prevent the hydrogel material from expanding radially inward and thus to limit the expansion of the hydrogel material in a radially outward direction along B2-B2 as depicted inFIG. 2B . Thus, in embodiments where a densely-woven cloth is used, it is preferred that the densely-woven cloth, when stretched around the circumference of a fully-expanded valve, does not permit the hydrogel material to migrate through the cloth and into the internal lumen of thestent 120. In a preferred embodiment in which theadaptive seal 130 is provided on a substrate, theadaptive seal 130 preferably expands only radially outwardly of theheart valve 100. - A hydrogel is generally understood to refer to a polymer or other material that expands or swells in response to an initiating condition, such as changes in temperature, electrical field, magnetic field, chemical environment, pH, and/or phase changes, for example, contact with a liquid. In a preferred embodiment, the adaptive seal does not comprise, or is not, a silicone polymer or other lubricous material. One type of hydrogel is a hydrophilic polymer which physically expands or swells when it contacts and absorbs a liquid, such as water. The extent of the physical expansion or swelling by a hydrophilic polymer is typically limited by the covalent or physical cross-links that oppose the absorption of water once the hydrogel reaches an equilibrium swelling state. Thus, the extent of expansion may be designed or tuned to preferred dimensions based on chemically modifying these crosslinkages. Hydrophilic polymers are highly absorbent and possess a degree of flexibility that is very similar to natural tissue due to their substantial water content.
- Examples of hydrophilic polymers, e.g., hydrogels, include, but are not limited to, poly(ethylene oxide), poly(hydroxyethyl methacrylate), poly(vinyl alcohol), polyacrylamide, poly(vinylpyrrolidone), poly(ethyloxazoline), poly(propylene oxide), poly(ethylene glycol)poloxamines, polyacrylamide, hydroxypropylmethacrylate (HPMA), poly(ethylene glycol), polymethacrylate, poly(methyl methacrylate)polylactic acid, carboxymethyl cellulose, hydroxyethyl cellulose, methylhydroxypropyl cellulose, polysucrose, hyaluronate, chondroitin sulfate, dextran, alginate, chitosan, gelatin, and derivatives, mixtures, and copolymers thereof.
- Hydrogels can be sensitive to stimuli and respond to changes in the surrounding environment, e.g., an initiating condition, such as changes in temperature, electrical field, magnetic field, chemical environment, pH, and/or phase changes, for example, contact with a liquid. The hydrogels contemplated for use in connection with bioprosthetic heart valves, as described herein, are initially provided in the contracted state and expand or swell only after exposure to an initiating condition. The rate and extent of swelling of the hydrogel can be configured by chemically modifying the hydrogel. For example, where it is desired to control or delay the start or the rate of swelling or expansion of the hydrogel upon exposure to the initiating condition, the hydrogel can be crosslinked with cross-linkers that degrade in response to being exposed to the same or a different initiating condition that causes the hydrogel to expand or swell.
- Thus, in a preferred embodiment the rate and extent of expansion of the hydrogel is controlled and fine-tuned by chemically modifying the hydrogel or by incorporating degradable cross-linkers. In a preferred embodiment, the adaptive seal is or comprises a delayed-swelling hydrogel which will not expand for a period of time after exposure to an initiating condition. This period of time is preferably at least 1 minute, more preferably at least 2 minutes, and most preferably at least 5 minutes. The delayed-swelling hydrogel can be produced by incorporating biodegradable cross-linkers in the hydrogel polymer to generate a delayed swelling hydrogel. Once the hydrogel is exposed to an initiating condition, the biodegradable cross-linkers can degrade at a desired rate to permit swelling at a corresponding rate after an initial exposure to the initiating condition. The cross-linkers can be selected to slowly degrade upon exposure to a physiological fluid, such as blood. As the cross-linkers degrade, the hydrogel will expand and swell.
- While the rate of hydrogel expansion can be controlled, it is understood that the hydrogel preferably reaches its full expansion, e.g., an equilibrium state, within a period of time to permit the implanting physician to confirm the absence of PVL of the implanted heart valve. In a preferred embodiment, the adaptive seal reaches its full expansion within 5 hours of implantation, preferably within 1 hour of implantation, and most preferably within 15 minutes of implantation. Thus, the biodegradable cross-linkers of the hydrogel are preferably completely degraded or severed within 5 hours, preferably within 1 hour, and most preferably within 15 minutes of exposure to the initiating condition.
-
FIGS. 3A and 3B depict asurgical heart valve 200 comprising a biologicaltissue leaflet structure 210 comprising three flexible leaflets and aframe 220 comprising three commissure posts. Asewing ring 225 defines the inflow portion of thevalve 200 and is used to attach thevalve 200 to the valve annulus. Thesewing ring 225 can be circular or scalloped. Thesewing ring 225 defines a suture-permeable cuff made of an inner body of silicone covered with a permeable or semi-permeable material or fabric. - In the embodiment depicted in
FIGS. 3A and 3B , theadaptive seal 230 is preferably a hydrogel which is exposed and coupled externally about the circumferential edge of thesewing ring 225 to provide conforming engagement between thesewing ring 225 and the inner surface of the annulus where the valve is implanted (not shown). Theadaptive seal 230 can also be provided inside thesewing ring 225, with a permeable or semi-permeable fabric covering being made of a material having sufficient elasticity to permit swelling and expansion of theadaptive seal 230 within thesewing ring 225. Alternatively, theadaptive seal 230 can also be provided as a hydrogel coating on thesewing ring 225 as a result of dipping the material or fabric constituting the sewing ring into a hydrogel solution. In the embodiment depicted inFIGS. 3A and 3B , theadaptive seal 230 comprises a hydrogel material that is disposed on a wire that is wrapped around thesewing ring 225 and preferably secured onto the sewing ring by adhesives or by sutures. Because thevalve 200 is surgically implanted and does not require thevalve 200 to be crimped or collapsed, the substrate for the hydrogel material is not required to be expandable or elastic. -
FIGS. 4A and 4B depict an embodiment of atranscatheter heart valve 300 which comprises anadaptive seal 330 a of a different configuration from the one depicted inFIGS. 1-2 . Theheart valve 300 comprises abiological tissue leaflet 310 attached to astent 320. Theheart valve 300 is further depicted as comprising a hydrogel-coatedwire 330 a surrounding the periphery of thestent 320. The hydrogel-coatedwire 330 a, by virtue of its geometry, comprising a plurality of loops, will permit expansion of theheart valve 300 for implantation. One or more hydro-gel coated wires can be used on the valve. - The hydrogel-coated
wire 330 a is formed as a plurality of loops. When theheart valve 300 is in its compressed or unexpanded configuration, as depicted inFIG. 4A , the hydrogel-coatedwire 330 a comprises a plurality of larger loops. When theheart valve 300 is in its expanded configuration, as depicted inFIG. 4B , the loops reduce in size significantly. The presence of the loops provides a degree of flexibility for radial expansion of theheart valve 300. - Suitable hydrogel-coated wires include Azur Peripheral HYDROCOIL® (MicroVention Terumo, Inc., Aliso Viejo, Calif.), which is a platinum coil with an expandable poly(acrylamide-co-acrylic acid) hydrogel and overcoiled with a stretched platinum coil. An advantage of using the hydrogel-coated
wire 330 a is that it stays substantially close to thestent 320 in both the expanded and the compressed states such that it does not significantly add material bulk. This permits the fabrication of transcatheter heart valves having substantially narrower delivery profiles than would be expected when such valves include a PVL skirt, for example. - In a preferred embodiment, at least one end of the hydrogel-coated wires is attached to the
stent 320 by crimping. In another preferred embodiment, the hydrogel-coated wires are crimped in one, two, three, or four locations along thestent 320. As depicted inFIGS. 4A and 4B , the hydrogel-coatedwire 330 a is positioned around the entire circumference of the heart valve at a distance from both theinflow end 302 and theoutflow end 304. In a preferred embodiment, the hydrogel-coatedwire 330 a undergoes limited expansion within the first 3 minutes, and fully expands within 20 minutes. - While
FIGS. 4A and 4B depict theadaptive seal 330 a taking the form of a hydrogel-coated wire, it is understood that theadaptive seal 330 a can also be provided as a hydrogel coating on thestent 320. In accordance with one aspect of this embodiment, thestent 320 can be dipped in or spray coated with a hydrogel solution and allowed to dry prior to assembling thestent 320 with thetissue leaflet 310. -
FIGS. 4C and 4D depict theheart valve 300 in which the hydrogel-coatedwire 330 b is provided in two different configurations. When thevalve 300 is in a compressed state, as depicted inFIG. 4C , the hydrogel-coatedwire 330 b is provided in a first configuration, in which the hydrogel-coatedwire 330 b is tightly coiled. When the valve is in an expanded state, as depicted inFIG. 4D , the hydrogel-coatedwire 330 b is provided in a second configuration, in which the hydrogel-coatedwire 330 b is substantially straight. The hydrogel-coatedwire 330 b can comprise a shape memory metal, such as Nitinol, such that it takes on the substantially straight configuration upon being heated to a particular temperature, preferably in the range of about 24-37° C. The temperature at which a shape memory metal, such as Nitinol, will change configurations can be fine-tuned by altering the profile of the shape memory metal. Alternatively, the hydrogel-coatedwire 330 b can be a non-metal wire that is elastically stretchable between the first and second configurations. It is understood that where an elastic wire is used, the elastic wire does not cause significant compression of thestent 320 in an expanded state. -
FIGS. 4E and 4F depict theheart valve 300 in which the hydrogel-coatedwire 330 c is provided as a straight wire that encircles or is coiled around the outer external periphery of theheart valve 300. In the preferred embodiment depicted inFIGS. 4E and 4F , the hydrogel-coatedwire 330 c has a length that permits it to be coiled around the entire outer circumference of the compressed valve (FIG. 4E ) more than once. Preferably, only one end of the hydrogel-coatedwire 330 c is affixed to thestent 320 by crimping. The other free end of the hydrogel-coatedwire 330 c is permitted to move in relation to thevalve 300 as it is expanded to the fully-expanded state (FIG. 4F ). In a preferred embodiment, the hydrogel-coatedwire 330 c has a length that permits it to be coiled around the heart valve in its fully-expanded state at least once, if not twice. One advantage provided by the hydrogel-coatedwire 330 c inFIGS. 4E-4F is that it will add, to a lesser event, to the delivery profile of thecompressed heart valve 300. -
FIGS. 5A and 5B depict an embodiment of areplacement heart valve 400 which can be implanted using minimally-invasive techniques. Theheart valve 400 comprises abiological tissue 410 coupled to a supportingframe 420 comprising three commissure posts, asewing ring 425 and aframe stent 430 comprising a cloth covered anchoring frame. Theframe stent 430 can be balloon expanded after implantation and is characterized as providing a greater area of engagement between theheart valve 400 and the arterial or cardiac walls. Theframe stent 430 therefore is believed to reduce the incidence of PVL of the implantedheart valve 400. In a preferred embodiment, theframe stent 430 or the cloth material constituting theframe stent 430 can be coated with the adaptive seal or hydrogel material. In another preferred embodiment, the adaptive seal or hydrogel material can be contained within the cloth material of theframe stent 430. - One advantage afforded by the
replacement heart valve 400 is that the manufacturing of the valve portion consisting of thebiological tissue 410, the supportingframe 420 and thesewing ring 425 can be done separately from the manufacture of the cloth-coveredframe stent 430 to constitute the adaptive seal. In the embodiment depicted inFIGS. 5A and 5B , the cloth coveredframe stent 430 is dipped in or sprayed with a hydrogel solution prior to assembly with the valve portion. Alternatively, the hydrogel material can be provided within the cloth coveredframe stent 430, provided that the cloth is sufficiently elastic to permit expansion by the hydrogel material contained therein. Once the valve portion and theframe stent 430 are separately prepared, the two can be assembled together. -
FIGS. 6A-6C depict an expandablebioprosthetic heart valve 600 and itsdelivery system 602 in the various stages from a collapsed delivery configuration with theadaptive seal 610 being adjacent the delivery system, as depicted inFIG. 6A , an intermediate configuration with theadaptive seal 610 is positioned around thebioprosthetic heart valve 600, as depicted inFIG. 6B , and an expanded configuration, in which theheart valve 600 is fully expanded and theadaptive seal 610 being disposed around theheart valve 600, as depicted inFIG. 6C . In a preferred embodiment, theadaptive seal 610 depicted inFIGS. 6A through 6C is a hydrogel-coated wire. - Expandable bioprosthetic heart valves are known in the art and the illustrated
heart valve 600 illustrated inFIGS. 6A through 6C is representative of a number of such valves which can be converted from a narrow constructed configuration to a wider expanded configuration. Typically, the valves are balloon expanded into position at a target annulus after having been advanced through the vasculature, although self-expanding valves are also known. The most common delivery routes commence at the femoral or carotid arteries, though other more direct routes through chest ports are also known. One such expandable prosthetic heart valve is the Edwards SAPIEN® or SAPIEN XT® Transcatheter Heart Valve available from Edwards Lifesciences of Irvine, Calif. The Edwards SAPIEN® valve can be placed either through a transfemoral or transapical approach. - The
delivery system 602 includes anelongated catheter 604 having anexpansion balloon 646 near a distal end thereof. Thebioprosthetic heart valve 600 mounts around theballoon 646 and is expanded thereby. The system further includesproximal connectors 608 for delivery of balloon inflation fluid, passage of a guide wire, or other such functions. In the exemplary embodiment, thebioprosthetic heart valve 600 includes a plurality of balloon expandable struts in between three axially-oriented commissure bars 605. Bioprosthetic tissue mounts within the framework created by the struts and bars 605, such as with supplementary fabric. - In most cases, it is desirable to reduce the delivery profile of the collapsed delivery configuration as depicted in
FIG. 6A . One way of achieving a reduced delivery profile is to provide theadaptive seal 610 such that it does not initially encircle or wrap the collapsedbioprosthetic heart valve 600 but instead is allowed to trail along the elongated catheter in a first delivery configuration. In a preferred embodiment, the collapsed delivery configuration depicted inFIG. 6A is provided within a sheath (not shown). Reducing the delivery profile of the collapsed delivery configuration will permit a reduced French size for the corresponding sheath. - As the delivery system is inserted into the vasculature of the patient's body, both the
bioprosthetic heart valve 600 and theadaptive seal 610 will be exposed to blood and other bodily fluids. As explained above, it is undesirable for theadaptive seal 610 to swell or expand substantially, if at all, immediately upon exposure to blood because such expansion will interfere with the ability to deliver thebioprosthetic heart valve 600 through the patient's vasculature and to advance thevalve 600 out of the delivery sheath. Thus, in a preferred embodiment, theadaptive seal 610 is chemically tuned such that it will respond to one or a plurality of initiating conditions, such as, for example, exposure to liquid and an additional condition, such as pH, temperature, a change in the electrical or magnetic field, or a change in the chemical environment, after a predetermined period of time of such exposure. In another embodiment, theadaptive seal 610 will include a biodegradable cross-linker which degrades at a predetermined rate upon exposure to an initiating condition. - Once the
bioprosthetic heart valve 600 is delivered proximate to the intended site of implantation, the sheath is removed. Upon removal of the sheath and before significant expansion of theheart valve 600, theadaptive seal 610 coils or wraps around the external periphery of theheart valve 600 in a second configuration. Theadaptive seal 610 can be comprised of a hydrogel material disposed on either a shape memory metal or other material that is configured to elastically wrap around theheart valve 600 once it is exposed from the sheath. In a preferred embodiment, the length of theadaptive seal 610 is longer than the circumference of the fully-expandedvalve 600 such that a portion of theadaptive seal 610 overlaps. In this manner, gaps between the two ends of theadaptive seal 610 can be avoided. - As indicated above, the
adaptive seal 610 preferably comprises a shape-memory material or metal, such as Nitinol, which is coated with a hydrogel and which is configured to coil around the outer circumference of thevalve 600 based reaching or exceeding a transformation temperature. In a preferred embodiment, the transformation temperature is between about 24-25° C., about 25-26° C., about 26-27° C., about 27-28° C., about 28-29° C., about 29-30° C., about 30-31° C., about 31-32° C., about 32-33° C., about 33-34° C., about 34-35° C., about 35-36° C., and about 36-37° C. In embodiments where thevalve 600 comprises a self-expanding stent made of shape-memory material or metal, the transformation temperature for the stent is higher than the transformation temperature for theadaptive seal 610 so as to ensure that theadaptive seal 610 coils around thevalve 600 before thevalve 600 begins to expand or is substantially or fully expanded. -
FIG. 6C depicts thebioprosthetic heart valve 600 in a fully-expanded configuration with theadaptive seal 610 being disposed around the circumference of thevalve 600. In a particularly preferred embodiment, theadaptive seal 610 does not swell or expand until after it assumes a fully expanded configuration as depicted inFIG. 6C . -
FIGS. 7A-7C depict the expandablebioprosthetic heart valve 600 having a hydrogel-coatedwire 610 a taking on different configurations that similarly permit a smaller delivery profile. The hydrogel-coatedwire 610 a is provided in a first delivery configuration as a straight wire, as depicted inFIG. 7A . This permits the compressedbioprosthetic heart valve 600 and itsdelivery system 602 to fit within a sheath having a reduced delivery profile. Once the sheath (not shown) is removed, the hydrogel-coatedwire 610 a takes on a second configuration, in which it is both coiled and wrapped around the outer periphery of theheart valve 600 at least two times (FIG. 7B ), and a third configuration, in which the hydrogel-coatedwire 610 a remains in a coiled configuration but is wrapped around the outer periphery of theheart valve 600 only once (FIG. 7C ). -
FIGS. 8A-8C depict the expandablebioprosthetic heart valve 600 having a hydrogel-coatedwire 610 b taking on another alternate configuration permitting a smaller delivery profile. The hydrogel-coatedwire 610 b is provided in a first delivery configuration as a straight wire, as depicted inFIG. 8A . This permits the compressedbioprosthetic heart valve 600 and itsdelivery system 602 to fit within a sheath having a reduced delivery profile. Once the sheath (not shown) is removed, the hydrogel-coatedwire 610 b takes on a second configuration, in which it is wrapped around the outer periphery of the heart valve 600 (FIGS. 8B and 8C ). Again, the length of the hydrogel-coatedwire 610 b is provided such that it encircles the external periphery of the compressed valve a plurality of times, preferably at least 2, 3, or 4 times (FIG. 8B ). As the hydrogel-coatedwire 610 b is coupled to the stent at only one end, theheart valve 600 is permitted to expand radially in its fully expanded state (FIG. 8C ). - With respect to the embodiments depicted in
FIGS. 6-8 , it is understood that theheart valve 600 can be packaged in a collapsed delivery configuration with the adaptive seal being positioned adjacent thedelivery system 602 as depicted inFIG. 6A , 7A or 8A. This allows theheart valve 600 to be provided to the implanting physician in a substantially ready-to-use condition out of the package. - As indicated above, the biological tissues suitable for the heart valves described herein are treated so as to permit storage without a liquid preservative solution, e.g., dry storage. To that end, the biological tissue can be contacted or immersed in a treatment solution comprising a polyhydric alcohol or polyol, preferably a glycerol. The glycerol can be provided in an aqueous, non-aqueous or a substantially non-aqueous solution. In a preferred embodiment, the non-aqueous solution (the solvent is not water) or the substantially non-aqueous solution is an alcoholic solution. In a preferred embodiment, the alcoholic solution comprises one or a combination of lower alcohols, preferably C1-C3 alcohols. The biological tissue following treatment with the treatment solution is dehydrated or substantially dehydrated. In a preferred embodiment, the water content of the biological tissue following treatment with the treatment solution is reduced at least about 10%, preferably at least about 25%, preferably at least about 50%, preferably at least about 75%, preferably at least about 80%, and preferably at least about 90%.
- The time of contact between the biological tissue and the treatment solution depends on the thickness and type of tissue. Once the biological tissue has been sufficiently exposed to the treatment solution, the tissue is removed from the solution and exposed to ambient air or an inert environment (e.g., nitrogen), at standard room temperature and humidity so as not to adversely affect tissue properties. Preferably, the drying is performed in a clean room or in a laminar flow bench at ambient room conditions for about 1 to 4 hours. In a preferred embodiment, the treatment solution is a solution of glycerol and a C1-C3 alcohol, wherein the treatment solution comprises about 60-95% by volume glycerol. Suitable treatment for the biological tissues are described in U.S. Pat. No. 8,007,992, issued Aug. 30, 2011, to Edwards Lifesciences Corp., the entire contents of which are incorporated herein by reference as if fully set forth herein. In another preferred embodiment, the tissue can be treated as described in U.S. Pat. No. 6,534,004, issued Mar. 18, 2003, issued to The Cleveland Clinic Foundation, the entire contents of which are incorporated herein by reference in its entirety as if fully set forth herein.
- In a preferred embodiment, the adaptive seal is made of a material that expands after exposure to one or more initiating conditions. The adaptive seal is preferably a hydrophilic polymer or a hydrogel-coated wire that is made up of a hydrogel material that expands or swells when exposed to an aqueous liquid, such as saline or blood. Preferably, the hydrogel material does not fully expand or swell until after a period of contact with the initiating condition (e.g., fluid), which provides physicians the ability to deliver and control the implantation of the device at the desired location. This can be accomplished by utilizing hydrogels or hydrogel-coated wires in which the hydrogel material has been cross-linked with a degradable cross-linker. Thus, the substantial expansion of the adaptive seal takes place after initial contact with the initiating condition. Alternatively, the seal can be made of a hydrogel that initially expands slowly and then expands more rapidly after a period of time has elapsed from exposure to the initiating condition. In a preferred embodiment, the rapid expansion of the adaptive seal occurs about 30 seconds, about 60 seconds, about 2 minutes, or about 5 minutes after exposure to the initiating condition. In embodiments where the initiating condition is exposure to fluid, preferably an aqueous fluid such as blood, the adaptive seal is provided in a substantially dehydrated state.
- The adaptive seal described herein can be provided in the form of a cloth, a film, a coating, a foam, or a hydrogel-coated wire and comprise an expandable material that impregnates a suitable substrate, is chemically coupled to a suitable substrate, or is contained within a permeable or semi-permeable barrier that permits the entry of fluid but contains the expandable material. The expandable material is preferably a hydrogel or an organic polymer that is cross-linked via covalent, ionic or hydrogen bonds to create a three-dimensional open lattice structure which entraps water molecules to form a gel. Alternatively, the adaptive seal is a hydrogel-coated wire, such as HYDROCOIL® (MicroVention Terumo, Inc., Aliso Viejo, Calif.), which is a platinum coil with an expandable poly(acrylamide-co-acrylic acid) hydrogel and overcoiled with a stretched platinum coil. When positioned in situ, the adaptive seal expands from its reduced radial profile to an increased radial profile. U.S. Patent Application Publication No. 2013/0190857, published Jul. 25, 2013, to Endoluminal Sciences Pty. Ltd. is incorporated herein by reference in its entirety.
- The bioprosthetic heart valve and adaptive seal can preferably be packaged in double sterile barrier packaging consisting of a rigid tray (PETG) with a TYVEK® non-woven polyolefin lid. The package is sealed in a cleanroom and sterilized in 100% ethylene oxide. Suitable packaging systems for the bioprosthetic heart valves disclosed herein are described in U.S. Patent Application Publication No. 2011/0214398, published Sep. 8, 2011, to Edwards Lifesciences Corp., and is incorporated herein by reference in its entirety. In embodiments where the bioprosthetic heart valve is provided along with a delivery device, suitable packaging systems are described in U.S. Patent Application Publication No. 2013/0152659, published Jun. 20, 2013; U.S. Patent Application Publication No. 2012/0158128, Jun. 21, 2012, and U.S. Patent Application Publication No. 2012/0239142, published Sep. 20, 2012, all to Edwards Lifesciences Corp, and all incorporated by reference herein in their entireties.
- The invention described and claimed herein is not to be limited in scope by the specific preferred embodiments disclosed herein, as these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
Claims (20)
1. A method for manufacturing a bioprosthetic heart valve comprising:
providing a bioprosthetic heart valve comprising a biological tissue that has been treated with a treatment solution comprising a polyhydric alcohol, the bioprosthetic heart valve having a periphery, an inflow portion and an outflow portion;
coupling an adaptive seal to the bioprosthetic heart valve, the adaptive seal comprising an expandable material that expands after exposure to an initiating condition; and
packaging the bioprosthetic heart valve and the coupled adaptive seal in a package that does not contain a liquid storage solution in contact with the bioprosthetic heart valve and the coupled adaptive seal.
2. The method of claim 1 , wherein the polyhydric alcohol is glycerol.
3. The method of claim 1 , wherein the biological tissue is at least partially dehydrated following treatment with the treatment solution.
4. The method of claim 1 , wherein the adaptive seal is a hydrophilic polymer or a hydrogel-coated wire.
5. The method of claim 4 , wherein the hydrophilic polymer or the hydrogel-coated wire comprises a biodegradable cross-linker and wherein expansion of the adaptive seal is delayed for a period of time after exposure to the initiating condition.
6. The method of claim 1 , wherein the initiating condition is one or more selected from the group consisting of: a change in temperature, a change in the electrical field, a change in the magnetic field, a change in the chemical environment, a change in pH, and contact with a liquid.
7. The method of claim 1 , wherein the expandable material expands longitudinally, radially, or both longitudinally and radially relative to the bioprosthetic heart valve after exposure to the initiating condition.
8. The method of claim 1 , wherein the bioprosthetic heart valve comprises a stent and wherein the coupling comprises coating the stent with the adaptive seal or coupling patches within open cells defined by the stent.
9. A packaged bioprosthetic heart valve comprising:
a bioprosthetic heart valve comprising a dehydrated biological tissue leaflet structure coupled to a supporting frame, the bioprosthetic heart valve having a periphery, an inflow portion, and an outflow portion;
an adaptive seal coupled to the bioprosthetic heart valve, the adaptive seal comprising an expandable material that expands after exposure to an initiating condition;
a sealed package containing the bioprosthetic heart valve and the adaptive seal, wherein the package does not contain a liquid storage solution in contact with the bioprosthetic heart valve and the adaptive seal.
10. The packaged bioprosthetic heart valve of claim 10 , wherein the adaptive seal is a hydrophilic polymer or a hydrogel-coated wire.
11. The packaged bioprosthetic heart valve of claim 10 , wherein the adaptive seal is a hydrogel comprising a biodegradable cross-linker and wherein expansion of the adaptive seal is delayed for a period of time after exposure to the initiating condition.
12. The packaged bioprosthetic heart valve of claim 11 , wherein the adaptive seal is a hydrogel-coated wire comprising a shape memory metal, the hydrogel-coated wire changing from a first configuration to a second configuration upon reaching or exceeding a transformation temperature.
13. The packaged bioprosthetic heart valve of claim 12 , wherein in the first configuration, the hydrogel-coated wire has one of a straight or a coiled configuration and wherein in the second configuration, the hydrogel-coated wire has the other of the straight or coiled configuration.
14. The packaged bioprosthetic heart valve of claim 9 , wherein the adaptive seal is coupled to the bioprosthetic heart valve at a spaced distance from both of the inflow and outflow portions.
15. The packaged bioprosthetic heart valve of claim 9 , wherein the adaptive seal is provided circumferentially about the bioprosthetic heart valve.
16. The packaged bioprosthetic heart valve of claim 15 , wherein the bioprosthetic heart valve further comprises a sewing ring and wherein the adaptive seal is coupled to and exposed from the sewing ring or contained within the sewing ring.
17. The packaged bioprosthetic heart valve of claim 9 , wherein the supporting frame is a stent comprising a plurality of struts and open cells.
18. The packaged bioprosthetic heart valve of claim 17 , wherein the adaptive seal is coupled to one or more struts of the supporting frame.
19. The packaged bioprosthetic heart valve of claim 17 , wherein the adaptive seal forms one of a coating on at least a portion of the stent.
20. The packaged bioprosthetic heart valve of claim 17 , wherein the adaptive seal is provided as patches disposed within the open cells defined by the stent.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/533,922 US20150122687A1 (en) | 2013-11-06 | 2014-11-05 | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
US15/792,441 US10722316B2 (en) | 2013-11-06 | 2017-10-24 | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
US16/938,899 US20200352670A1 (en) | 2013-11-06 | 2020-07-24 | Bioprosthetic heart valves having adaptive seals to minimize perivalvular leakage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361900827P | 2013-11-06 | 2013-11-06 | |
US14/533,922 US20150122687A1 (en) | 2013-11-06 | 2014-11-05 | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/792,441 Continuation US10722316B2 (en) | 2013-11-06 | 2017-10-24 | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150122687A1 true US20150122687A1 (en) | 2015-05-07 |
Family
ID=53006205
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/533,922 Abandoned US20150122687A1 (en) | 2013-11-06 | 2014-11-05 | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
US15/792,441 Active 2035-02-27 US10722316B2 (en) | 2013-11-06 | 2017-10-24 | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
US16/938,899 Pending US20200352670A1 (en) | 2013-11-06 | 2020-07-24 | Bioprosthetic heart valves having adaptive seals to minimize perivalvular leakage |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/792,441 Active 2035-02-27 US10722316B2 (en) | 2013-11-06 | 2017-10-24 | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
US16/938,899 Pending US20200352670A1 (en) | 2013-11-06 | 2020-07-24 | Bioprosthetic heart valves having adaptive seals to minimize perivalvular leakage |
Country Status (1)
Country | Link |
---|---|
US (3) | US20150122687A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140243966A1 (en) * | 2013-02-01 | 2014-08-28 | Medtronic, Inc. | Anti-Paravalvular Leakage Component for a Transcatheter Valve Prosthesis |
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
US20170209261A1 (en) * | 2011-09-12 | 2017-07-27 | Highlife Sas | Transcatheter valve prosthesis |
US20170266002A1 (en) * | 2007-01-19 | 2017-09-21 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
US9974649B2 (en) | 2016-03-24 | 2018-05-22 | Medtronic Vascular, Inc. | Stented prosthetic heart valve having wrap and methods of delivery and deployment |
US10166097B2 (en) | 2009-09-29 | 2019-01-01 | Edwards Lifesciences Cardiaq Llc | Replacement heart valve and method |
US10433993B2 (en) | 2017-01-20 | 2019-10-08 | Medtronic Vascular, Inc. | Valve prosthesis having a radially-expandable sleeve integrated thereon for delivery and prevention of paravalvular leakage |
CN110769782A (en) * | 2017-05-12 | 2020-02-07 | 爱德华兹生命科学公司 | Prosthetic heart valve docking assembly |
US20200078161A1 (en) * | 2018-09-10 | 2020-03-12 | Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen | Endovascular stent grafts and methods of using said stent grafts |
US10888420B2 (en) | 2016-03-14 | 2021-01-12 | Medtronic Vascular, Inc. | Stented prosthetic heart valve having a wrap and delivery devices |
US20210315679A1 (en) * | 2017-05-02 | 2021-10-14 | Medtronic Vascular, Inc. | Assemblies and methods of sterilizing a wet stored prosthetic heart valve |
US11344399B2 (en) | 2017-05-02 | 2022-05-31 | Medtronic Vascular, Inc. | Packaging for dry tissue prosthetic heart valve |
WO2022236928A1 (en) * | 2021-05-08 | 2022-11-17 | 上海臻亿医疗科技有限公司 | Anchoring device for cardiac implant prosthesis and cardiac implant prosthesis comprising same |
WO2022236929A1 (en) * | 2021-05-14 | 2022-11-17 | 上海臻亿医疗科技有限公司 | Heart valve prosthesis apparatus |
US11969329B2 (en) | 2022-05-03 | 2024-04-30 | Medtronic Vascular, Inc. | Packaging for dry tissue prosthetic heart valve |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202016105963U1 (en) * | 2016-10-24 | 2018-01-25 | Nvt Ag | Intraluminal vascular prosthesis for implantation in the heart or cardiac vessels of a patient |
WO2022164811A1 (en) | 2021-01-26 | 2022-08-04 | Edwards Lifesciences Corporation | 3-d shaped skirts for prosthetic heart valves |
US20220265450A1 (en) * | 2021-02-24 | 2022-08-25 | Medtronic, Inc. | Skirt-reinforcement members for prosthetic valve devices |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5549663A (en) * | 1994-03-09 | 1996-08-27 | Cordis Corporation | Endoprosthesis having graft member and exposed welded end junctions, method and procedure |
US20030100920A1 (en) * | 1999-07-28 | 2003-05-29 | Akin Jodi J. | Devices and methods for interconnecting conduits and closing openings in tissue |
US20050137690A1 (en) * | 2003-12-23 | 2005-06-23 | Sadra Medical | Low profile heart valve and delivery system |
US7220274B1 (en) * | 2003-03-21 | 2007-05-22 | Quinn Stephen F | Intravascular stent grafts and methods for deploying the same |
US20070244544A1 (en) * | 2006-04-14 | 2007-10-18 | Medtronic Vascular, Inc. | Seal for Enhanced Stented Valve Fixation |
US20090088836A1 (en) * | 2007-08-23 | 2009-04-02 | Direct Flow Medical, Inc. | Translumenally implantable heart valve with formed in place support |
US20090164005A1 (en) * | 2007-12-21 | 2009-06-25 | Edwards Lifesciences Corporation | Capping Bioprosthetic Tissue to Reduce Calcification |
US20110004299A1 (en) * | 2006-02-18 | 2011-01-06 | The Cleveland Clinic Foundation | Apparatus and method for replacing a diseased cardiac valve |
US20110214398A1 (en) * | 2010-03-05 | 2011-09-08 | Edwards Lifesciences Corporation | Dry Prosthetic Heart Valve Packaging System |
US20110311493A1 (en) * | 2010-06-17 | 2011-12-22 | Dove Jeffrey S | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
US20120290079A1 (en) * | 2011-05-12 | 2012-11-15 | Edwards Lifesciences Corporation | Mitral heart valve holder and storage system |
US20130190857A1 (en) * | 2011-09-09 | 2013-07-25 | Endoluminal Sciences Pty Ltd. | Means for controlled sealing of endovascular devices |
US20130197622A1 (en) * | 2011-09-09 | 2013-08-01 | Endoluminal Sciences Pty Ltd | Means for Controlled Sealing of Endovascular Devices |
US8517027B2 (en) * | 2004-09-03 | 2013-08-27 | Boston Scientific Scimed, Inc. | Reversible vessel seal |
US20130331929A1 (en) * | 2011-09-09 | 2013-12-12 | Endoluminal Sciences Pty Ltd. | Means for Controlled Sealing of Endovascular Devices |
US8839957B2 (en) * | 2010-02-15 | 2014-09-23 | Michael C. Murad | Prosthetic heart valve packaging system |
Family Cites Families (266)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU116573A1 (en) | 1958-01-07 | 1958-11-30 | В.В. Церлин | Method for colorimetric determination of nitrogen, phosphorus and potassium in plants |
US3143742A (en) | 1963-03-19 | 1964-08-11 | Surgitool Inc | Prosthetic sutureless heart valve |
US3320972A (en) | 1964-04-16 | 1967-05-23 | Roy F High | Prosthetic tricuspid valve and method of and device for fabricating same |
US3371352A (en) | 1965-01-19 | 1968-03-05 | Edwards Lab Inc | Heart valve for quick implantation having provision for ingrowth of tissue |
US3546710A (en) | 1965-12-11 | 1970-12-15 | Valery Ivanovich Shumakov | Cardiac valve prosthesis for sutureless fixation |
US3574865A (en) | 1968-08-08 | 1971-04-13 | Michigan Instr Inc | Prosthetic sutureless heart valve |
USRE30912E (en) | 1968-09-16 | 1982-04-27 | Hancock Laboratories, Inc. | Stent for heart valve |
US3755823A (en) | 1971-04-23 | 1973-09-04 | Hancock Laboratories Inc | Flexible stent for heart valve |
US3839741A (en) | 1972-11-17 | 1974-10-08 | J Haller | Heart valve and retaining means therefor |
US3997923A (en) | 1975-04-28 | 1976-12-21 | St. Jude Medical, Inc. | Heart valve prosthesis and suturing assembly and method of implanting a heart valve prosthesis in a heart |
US4340091A (en) | 1975-05-07 | 1982-07-20 | Albany International Corp. | Elastomeric sheet materials for heart valve and other prosthetic implants |
FR2298313A1 (en) | 1975-06-23 | 1976-08-20 | Usifroid | LINEAR REDUCER FOR VALVULOPLASTY |
US4035849A (en) | 1975-11-17 | 1977-07-19 | William W. Angell | Heart valve stent and process for preparing a stented heart valve prosthesis |
AR206762A1 (en) | 1976-01-01 | 1976-08-13 | Pisanu A | LOW PROFILE BIOPROTHESIS DERIVED FROM PORCINE HETEROLOGICAL AORTIC VALVE |
CA1069652A (en) | 1976-01-09 | 1980-01-15 | Alain F. Carpentier | Supported bioprosthetic heart valve with compliant orifice ring |
US4084268A (en) | 1976-04-22 | 1978-04-18 | Shiley Laboratories, Incorporated | Prosthetic tissue heart valve |
US4078468A (en) | 1976-10-21 | 1978-03-14 | Simon Civitello | Apparatus for extending a lower range of a stringed musical instrument |
DK229077A (en) | 1977-05-25 | 1978-11-26 | Biocoating Aps | HEARTBALL PROSTHET AND PROCEDURE FOR MANUFACTURING IT |
US4172295A (en) | 1978-01-27 | 1979-10-30 | Shiley Scientific, Inc. | Tri-cuspid three-tissue prosthetic heart valve |
AR221872A1 (en) | 1979-03-16 | 1981-03-31 | Liotta Domingo S | IMPROVEMENTS IN IMPANTABLE HEART VALVES |
GB2056023B (en) | 1979-08-06 | 1983-08-10 | Ross D N Bodnar E | Stent for a cardiac valve |
US4388735A (en) | 1980-11-03 | 1983-06-21 | Shiley Inc. | Low profile prosthetic xenograft heart valve |
EP0125393B1 (en) | 1980-11-03 | 1987-12-09 | Shiley Incorporated | Prosthetic heart valve |
US4470157A (en) | 1981-04-27 | 1984-09-11 | Love Jack W | Tricuspid prosthetic tissue heart valve |
US4364126A (en) | 1981-07-28 | 1982-12-21 | Vascor, Inc. | Heart valve with removable cusp protector band |
US4501030A (en) | 1981-08-17 | 1985-02-26 | American Hospital Supply Corporation | Method of leaflet attachment for prosthetic heart valves |
US4451936A (en) | 1981-12-21 | 1984-06-05 | American Hospital Supply Corporation | Supra-annular aortic valve |
ATE21330T1 (en) | 1982-01-20 | 1986-08-15 | Martin Morris Black | ARTIFICIAL HEART VALVES. |
US4680031A (en) | 1982-11-29 | 1987-07-14 | Tascon Medical Technology Corporation | Heart valve prosthesis |
GB8300636D0 (en) | 1983-01-11 | 1983-02-09 | Black M M | Heart valve replacements |
US4506394A (en) | 1983-01-13 | 1985-03-26 | Molrose Management, Ltd. | Cardiac valve prosthesis holder |
US4535483A (en) | 1983-01-17 | 1985-08-20 | Hemex, Inc. | Suture rings for heart valves |
FR2543834B1 (en) | 1983-04-07 | 1985-08-23 | Descartes Universite Rene | VARIABLE GEOMETRY PROBE FOR MEASURING RADIAL CONSTRAINTS IN A SPHINCTER OF A LIVING ORGANISM |
AR229309A1 (en) | 1983-04-20 | 1983-07-15 | Barone Hector Daniel | MOUNT FOR CARDIAC VALVES |
US4626255A (en) | 1983-09-23 | 1986-12-02 | Christian Weinhold | Heart valve bioprothesis |
DE8327414U1 (en) | 1983-09-23 | 1984-02-02 | Reichart, Bruno, Prof. Dr. | HEART VALVE PROSTHESIS |
US4629459A (en) | 1983-12-28 | 1986-12-16 | Shiley Inc. | Alternate stent covering for tissue valves |
GB8424582D0 (en) | 1984-09-28 | 1984-11-07 | Univ Glasgow | Heart valve prosthesis |
NL8500538A (en) | 1985-02-26 | 1986-09-16 | Stichting Tech Wetenschapp | HEART VALVE PROSTHESIS, METHOD FOR MANUFACTURING A HEART VALVE PROSTHESIS AND MOLD USED THEREIN |
US4888009A (en) | 1985-04-05 | 1989-12-19 | Abiomed, Inc. | Prosthetic heart valve |
DE3541478A1 (en) | 1985-11-23 | 1987-05-27 | Beiersdorf Ag | HEART VALVE PROSTHESIS AND METHOD FOR THE PRODUCTION THEREOF |
US4790843A (en) | 1986-06-16 | 1988-12-13 | Baxter Travenol Laboratories, Inc. | Prosthetic heart valve assembly |
US4725274A (en) | 1986-10-24 | 1988-02-16 | Baxter Travenol Laboratories, Inc. | Prosthetic heart valve |
US4914097A (en) | 1987-02-25 | 1990-04-03 | Mitsubishi Kasei Corporation | N-indanyl carboxamide derivative and agricultural/horticultural fungicide containing the derivative as active ingredient |
SU1697790A1 (en) | 1987-03-02 | 1991-12-15 | Сибирский физико-технический институт им.В.Д.Кузнецова при Томском государственном университете им.В.В.Куйбышева | Heart valve prosthesis with mechanical fixing |
US4851000A (en) | 1987-07-31 | 1989-07-25 | Pacific Biomedical Holdings, Ltd. | Bioprosthetic valve stent |
US5010892A (en) | 1988-05-04 | 1991-04-30 | Triangle Research And Development Corp. | Body lumen measuring instrument |
US4960424A (en) | 1988-06-30 | 1990-10-02 | Grooters Ronald K | Method of replacing a defective atrio-ventricular valve with a total atrio-ventricular valve bioprosthesis |
US5032128A (en) | 1988-07-07 | 1991-07-16 | Medtronic, Inc. | Heart valve prosthesis |
US5697375A (en) | 1989-09-18 | 1997-12-16 | The Research Foundation Of State University Of New York | Method and apparatus utilizing heart sounds for determining pressures associated with the left atrium |
US4993428A (en) | 1990-02-12 | 1991-02-19 | Microstrain Company | Method of and means for implanting a pressure and force sensing apparatus |
US5147391A (en) | 1990-04-11 | 1992-09-15 | Carbomedics, Inc. | Bioprosthetic heart valve with semi-permeable commissure posts and deformable leaflets |
US5037434A (en) | 1990-04-11 | 1991-08-06 | Carbomedics, Inc. | Bioprosthetic heart valve with elastic commissures |
DK124690D0 (en) | 1990-05-18 | 1990-05-18 | Henning Rud Andersen | FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION |
US5755782A (en) | 1991-01-24 | 1998-05-26 | Autogenics | Stents for autologous tissue heart valve |
US5489298A (en) | 1991-01-24 | 1996-02-06 | Autogenics | Rapid assembly concentric mating stent, tissue heart valve with enhanced clamping and tissue exposure |
US5163955A (en) | 1991-01-24 | 1992-11-17 | Autogenics | Rapid assembly, concentric mating stent, tissue heart valve with enhanced clamping and tissue alignment |
ES2028611A6 (en) | 1991-02-07 | 1992-07-01 | Garcia Gonzalez Moro Jose Beni | Artificial heart valve. |
JPH05184611A (en) | 1991-03-19 | 1993-07-27 | Kenji Kusuhara | Valvular annulation retaining member and its attaching method |
EP0583316B1 (en) | 1991-05-08 | 1996-12-11 | Nika Health Products Limited | Process and apparatus for the production of a heart valve prosthesis |
RU2124332C1 (en) | 1991-05-08 | 1999-01-10 | Ника Хелт Продактс Лимитид | Plastic-material support for heart valve prosthesis |
US5397351A (en) | 1991-05-13 | 1995-03-14 | Pavcnik; Dusan | Prosthetic valve for percutaneous insertion |
US5370685A (en) | 1991-07-16 | 1994-12-06 | Stanford Surgical Technologies, Inc. | Endovascular aortic valve replacement |
US5571215A (en) | 1993-02-22 | 1996-11-05 | Heartport, Inc. | Devices and methods for intracardiac procedures |
US5584803A (en) | 1991-07-16 | 1996-12-17 | Heartport, Inc. | System for cardiac procedures |
US5704361A (en) | 1991-11-08 | 1998-01-06 | Mayo Foundation For Medical Education And Research | Volumetric image ultrasound transducer underfluid catheter system |
US5258021A (en) | 1992-01-27 | 1993-11-02 | Duran Carlos G | Sigmoid valve annuloplasty ring |
US5489297A (en) | 1992-01-27 | 1996-02-06 | Duran; Carlos M. G. | Bioprosthetic heart valve with absorbable stent |
US5258023A (en) | 1992-02-12 | 1993-11-02 | Reger Medical Development, Inc. | Prosthetic heart valve |
GB9206449D0 (en) | 1992-03-25 | 1992-05-06 | Univ Leeds | Artificial heart valve |
US5332402A (en) | 1992-05-12 | 1994-07-26 | Teitelbaum George P | Percutaneously-inserted cardiac valve |
US5316016A (en) | 1992-07-07 | 1994-05-31 | Scimed Life Systems, Inc. | Imaging balloon catheter and methods for use and manufacture |
DE4222610A1 (en) | 1992-07-10 | 1994-01-13 | Jansen Josef Dr Ing | Support housing for flap and closing elements |
US5449384A (en) | 1992-09-28 | 1995-09-12 | Medtronic, Inc. | Dynamic annulus heart valve employing preserved porcine valve leaflets |
US5336178A (en) | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5814097A (en) | 1992-12-03 | 1998-09-29 | Heartport, Inc. | Devices and methods for intracardiac procedures |
US6283127B1 (en) | 1992-12-03 | 2001-09-04 | Wesley D. Sterman | Devices and methods for intracardiac procedures |
US6010531A (en) | 1993-02-22 | 2000-01-04 | Heartport, Inc. | Less-invasive devices and methods for cardiac valve surgery |
US5713951A (en) | 1993-02-22 | 1998-02-03 | Heartport, Inc. | Thoracoscopic valve prosthesis delivery device |
US5431676A (en) | 1993-03-05 | 1995-07-11 | Innerdyne Medical, Inc. | Trocar system having expandable port |
GB9312666D0 (en) | 1993-06-18 | 1993-08-04 | Vesely Ivan | Bioprostetic heart valve |
US5396887A (en) | 1993-09-23 | 1995-03-14 | Cardiac Pathways Corporation | Apparatus and method for detecting contact pressure |
US5360014A (en) | 1993-11-10 | 1994-11-01 | Carbomedics, Inc. | Sizing apparatus for heart valve with supra annular suture ring |
US5489296A (en) | 1993-12-17 | 1996-02-06 | Autogenics | Heart valve measurement tool |
US5425741A (en) | 1993-12-17 | 1995-06-20 | Autogenics | Tissue cutting die |
WO1995017139A1 (en) | 1993-12-22 | 1995-06-29 | Nicomo Ab | Cardiac valve holders |
EP0705081B1 (en) | 1994-04-22 | 2001-10-17 | Medtronic, Inc. | Stented bioprosthetic heart valve |
GB9408314D0 (en) | 1994-04-27 | 1994-06-15 | Cardio Carbon Co Ltd | Heart valve prosthesis |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
US5573007A (en) | 1994-08-08 | 1996-11-12 | Innerspace, Inc. | Gas column pressure monitoring catheters |
US5533515A (en) | 1994-08-11 | 1996-07-09 | Foster-Miller | Solid state sphincter myometers |
US5545133A (en) | 1994-09-16 | 1996-08-13 | Scimed Life Systems, Inc. | Balloon catheter with improved pressure source |
US5562729A (en) | 1994-11-01 | 1996-10-08 | Biocontrol Technology, Inc. | Heart valve |
US5618307A (en) | 1995-04-03 | 1997-04-08 | Heartport, Inc. | Clamp assembly and method of use |
US5626607A (en) | 1995-04-03 | 1997-05-06 | Heartport, Inc. | Clamp assembly and method of use |
US5752522A (en) | 1995-05-04 | 1998-05-19 | Cardiovascular Concepts, Inc. | Lesion diameter measurement catheter and method |
US5824064A (en) | 1995-05-05 | 1998-10-20 | Taheri; Syde A. | Technique for aortic valve replacement with simultaneous aortic arch graft insertion and apparatus therefor |
US5578076A (en) | 1995-05-24 | 1996-11-26 | St. Jude Medical, Inc. | Low profile holder for heart valve prosthesis |
US5716417A (en) | 1995-06-07 | 1998-02-10 | St. Jude Medical, Inc. | Integral supporting structure for bioprosthetic heart valve |
US5728152A (en) | 1995-06-07 | 1998-03-17 | St. Jude Medical, Inc. | Bioresorbable heart valve support |
US5814098A (en) | 1995-06-07 | 1998-09-29 | St. Jude Medical, Inc. | Adjustable sizing apparatus |
US5628789A (en) | 1995-09-11 | 1997-05-13 | St. Jude Medical, Inc. | Apparatus for attachment of heart valve holder to heart valve prosthesis |
US5713952A (en) | 1995-09-11 | 1998-02-03 | St. Jude Medical, Inc. | Apparatus for attachment of heart valve holder to heart valve prosthesis |
US5695503A (en) | 1995-09-14 | 1997-12-09 | St. Jude Medical, Inc. | Apparatus for attachment of heart valve holder to heart valve prosthesis |
GB9519194D0 (en) | 1995-09-20 | 1995-11-22 | Univ Wales Medicine | Anorectal angle measurement |
US6162233A (en) | 1996-02-23 | 2000-12-19 | Cardiovascular Technologies, Llc | Wire fasteners for use in minimally invasive surgery and means and methods for handling those fasteners |
US5716370A (en) | 1996-02-23 | 1998-02-10 | Williamson, Iv; Warren | Means for replacing a heart valve in a minimally invasive manner |
US20020068949A1 (en) | 1996-02-23 | 2002-06-06 | Williamson Warren P. | Extremely long wire fasteners for use in minimally invasive surgery and means and method for handling those fasteners |
US6402780B2 (en) | 1996-02-23 | 2002-06-11 | Cardiovascular Technologies, L.L.C. | Means and method of replacing a heart valve in a minimally invasive manner |
US5891160A (en) | 1996-02-23 | 1999-04-06 | Cardiovascular Technologies, Llc | Fastener delivery and deployment mechanism and method for placing the fastener in minimally invasive surgery |
US5972004A (en) | 1996-02-23 | 1999-10-26 | Cardiovascular Technologies, Llc. | Wire fasteners for use in minimally invasive surgery and apparatus and methods for handling those fasteners |
US5885228A (en) | 1996-05-08 | 1999-03-23 | Heartport, Inc. | Valve sizer and method of use |
EP0897285A4 (en) | 1996-05-10 | 2000-03-08 | Cardiovascular Concepts Inc | Lesion diameter measurement catheter and method |
SE506299C2 (en) | 1996-05-20 | 1997-12-01 | Bertil Oredsson | Transducer to detect changes in cross-section of an elongated body cavity |
US5855601A (en) | 1996-06-21 | 1999-01-05 | The Trustees Of Columbia University In The City Of New York | Artificial heart valve and method and device for implanting the same |
DE19632263C1 (en) | 1996-08-09 | 1998-01-08 | Domed Medizintechnik Gmbh | Method and device for venous compression plethysmography |
US5848969A (en) | 1996-10-28 | 1998-12-15 | Ep Technologies, Inc. | Systems and methods for visualizing interior tissue regions using expandable imaging structures |
US5766240A (en) | 1996-10-28 | 1998-06-16 | Medtronic, Inc. | Rotatable suturing ring for prosthetic heart valve |
US5919147A (en) | 1996-11-01 | 1999-07-06 | Jain; Krishna M. | Method and apparatus for measuring the vascular diameter of a vessel |
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
US5924984A (en) | 1997-01-30 | 1999-07-20 | University Of Iowa Research Foundation | Anorectal probe apparatus having at least one muscular activity sensor |
US5908450A (en) | 1997-02-28 | 1999-06-01 | Medtronic, Inc. | Physiologic mitral valve implantation holding system |
US5928281A (en) | 1997-03-27 | 1999-07-27 | Baxter International Inc. | Tissue heart valves |
US5833605A (en) | 1997-03-28 | 1998-11-10 | Shah; Ajit | Apparatus for vascular mapping and methods of use |
US5957949A (en) | 1997-05-01 | 1999-09-28 | World Medical Manufacturing Corp. | Percutaneous placement valve stent |
US6245102B1 (en) | 1997-05-07 | 2001-06-12 | Iowa-India Investments Company Ltd. | Stent, stent graft and stent valve |
AU9225598A (en) | 1997-09-04 | 1999-03-22 | Endocore, Inc. | Artificial chordae replacement |
US5984959A (en) | 1997-09-19 | 1999-11-16 | United States Surgical | Heart valve replacement tools and procedures |
US5921934A (en) | 1997-11-25 | 1999-07-13 | Scimed Life Systems, Inc. | Methods and apparatus for non-uniform rotation distortion detection in an intravascular ultrasound imaging system |
US6530952B2 (en) | 1997-12-29 | 2003-03-11 | The Cleveland Clinic Foundation | Bioprosthetic cardiovascular valve system |
FR2776912B1 (en) | 1998-04-06 | 2000-08-04 | Houari Lofti | DEVICE FOR THE OPERATIVE OPERATION OF THE CARDIO-CIRCULATORY APPARATUS OF THE HUMAN OR ANIMAL BODY |
US6176877B1 (en) | 1998-04-20 | 2001-01-23 | St. Jude Medical, Inc. | Two piece prosthetic heart valve |
US6074418A (en) | 1998-04-20 | 2000-06-13 | St. Jude Medical, Inc. | Driver tool for heart valve prosthesis fasteners |
WO1999058082A2 (en) | 1998-05-14 | 1999-11-18 | The Cleveland Clinic Foundation | Processing of implantable animal tissues for dry storage |
US6630001B2 (en) | 1998-06-24 | 2003-10-07 | International Heart Institute Of Montana Foundation | Compliant dehyrated tissue for implantation and process of making the same |
US20030217415A1 (en) | 1998-06-30 | 2003-11-27 | Katrina Crouch | Plasticized bone grafts and methods of making and using same |
US6106550A (en) | 1998-07-10 | 2000-08-22 | Sulzer Carbomedics Inc. | Implantable attaching ring |
US6197054B1 (en) | 1998-09-01 | 2001-03-06 | Sulzer Carbomedics Inc. | Sutureless cuff for heart valves |
US6334873B1 (en) | 1998-09-28 | 2002-01-01 | Autogenics | Heart valve having tissue retention with anchors and an outer sheath |
US6066160A (en) | 1998-11-23 | 2000-05-23 | Quickie Llc | Passive knotless suture terminator for use in minimally invasive surgery and to facilitate standard tissue securing |
US6264611B1 (en) | 1998-11-25 | 2001-07-24 | Ball Semiconductor, Inc. | Monitor for interventional procedures |
US6126007A (en) | 1998-12-30 | 2000-10-03 | St. Jude Medical, Inc. | Tissue valve holder |
US6896690B1 (en) | 2000-01-27 | 2005-05-24 | Viacor, Inc. | Cardiac valve procedure methods and devices |
US6425916B1 (en) | 1999-02-10 | 2002-07-30 | Michi E. Garrison | Methods and devices for implanting cardiac valves |
EP2078498B1 (en) | 1999-04-09 | 2010-12-22 | Evalve, Inc. | Apparatus for cardiac valve repair |
EP1171059B1 (en) | 1999-04-23 | 2005-11-02 | St. Jude Medical ATG, Inc. | Artificial heart valve attachment apparatus |
US7147663B1 (en) | 1999-04-23 | 2006-12-12 | St. Jude Medical Atg, Inc. | Artificial heart valve attachment apparatus and methods |
US6790229B1 (en) | 1999-05-25 | 2004-09-14 | Eric Berreklouw | Fixing device, in particular for fixing to vascular wall tissue |
US6217611B1 (en) | 1999-05-26 | 2001-04-17 | Sulzer Carbomedics Inc. | Modular heart valve prothesis |
US6287339B1 (en) | 1999-05-27 | 2001-09-11 | Sulzer Carbomedics Inc. | Sutureless heart valve prosthesis |
US6241765B1 (en) | 1999-07-15 | 2001-06-05 | Sulzer Carbomedics Inc. | Stapled heart prosthesis and method of installing same |
US6312465B1 (en) | 1999-07-23 | 2001-11-06 | Sulzer Carbomedics Inc. | Heart valve prosthesis with a resiliently deformable retaining member |
US6231561B1 (en) | 1999-09-20 | 2001-05-15 | Appriva Medical, Inc. | Method and apparatus for closing a body lumen |
DE19945587A1 (en) | 1999-09-23 | 2001-05-10 | Co Don Ag | Procedure for inserting implants into human organs |
US6371983B1 (en) | 1999-10-04 | 2002-04-16 | Ernest Lane | Bioprosthetic heart valve |
US6312447B1 (en) | 1999-10-13 | 2001-11-06 | The General Hospital Corporation | Devices and methods for percutaneous mitral valve repair |
US6440164B1 (en) | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
US8579966B2 (en) | 1999-11-17 | 2013-11-12 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
US6598307B2 (en) | 1999-11-17 | 2003-07-29 | Jack W. Love | Device and method for assessing the geometry of a heart valve |
US20070043435A1 (en) | 1999-11-17 | 2007-02-22 | Jacques Seguin | Non-cylindrical prosthetic valve system for transluminal delivery |
US7195641B2 (en) | 1999-11-19 | 2007-03-27 | Advanced Bio Prosthetic Surfaces, Ltd. | Valvular prostheses having metal or pseudometallic construction and methods of manufacture |
US6458153B1 (en) | 1999-12-31 | 2002-10-01 | Abps Venture One, Ltd. | Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof |
US20010041914A1 (en) | 1999-11-22 | 2001-11-15 | Frazier Andrew G.C. | Tissue patch deployment catheter |
US6479079B1 (en) | 1999-12-13 | 2002-11-12 | Sulzer Carbomedics Inc. | Anticalcification treatments for fixed biomaterials |
MXPA02007253A (en) | 2000-01-27 | 2003-09-22 | 3F Therapeutics Inc | Prosthetic heart valve. |
DE60128069D1 (en) | 2000-01-31 | 2007-06-06 | Cook Biotech Inc | STENT VALVE FLAP |
US6821297B2 (en) | 2000-02-02 | 2004-11-23 | Robert V. Snyders | Artificial heart valve, implantation instrument and method therefor |
DE10010074B4 (en) | 2000-02-28 | 2005-04-14 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Device for fastening and anchoring heart valve prostheses |
DE10010073B4 (en) | 2000-02-28 | 2005-12-22 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anchoring for implantable heart valve prostheses |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US6468305B1 (en) | 2000-05-16 | 2002-10-22 | St. Jude Medical, Inc. | Two piece valve |
US6805711B2 (en) | 2000-06-02 | 2004-10-19 | 3F Therapeutics, Inc. | Expandable medical implant and percutaneous delivery |
WO2002019951A1 (en) | 2000-09-07 | 2002-03-14 | Viacor, Inc. | Fixation band for affixing a prosthetic heart valve to tissue |
WO2002022054A1 (en) | 2000-09-12 | 2002-03-21 | Gabbay S | Valvular prosthesis and method of using same |
US7510572B2 (en) | 2000-09-12 | 2009-03-31 | Shlomo Gabbay | Implantation system for delivery of a heart valve prosthesis |
US6893459B1 (en) | 2000-09-20 | 2005-05-17 | Ample Medical, Inc. | Heart valve annulus device and method of using same |
US6966925B2 (en) | 2000-12-21 | 2005-11-22 | Edwards Lifesciences Corporation | Heart valve holder and method for resisting suture looping |
US8038708B2 (en) | 2001-02-05 | 2011-10-18 | Cook Medical Technologies Llc | Implantable device with remodelable material and covering material |
US6733525B2 (en) | 2001-03-23 | 2004-05-11 | Edwards Lifesciences Corporation | Rolled minimally-invasive heart valves and methods of use |
US7374571B2 (en) | 2001-03-23 | 2008-05-20 | Edwards Lifesciences Corporation | Rolled minimally-invasive heart valves and methods of manufacture |
DK1245202T3 (en) | 2001-03-27 | 2004-08-30 | Cook William Europ | Aortic device |
DE10121210B4 (en) | 2001-04-30 | 2005-11-17 | Universitätsklinikum Freiburg | Anchoring element for the intraluminal anchoring of a heart valve replacement and method for its production |
FR2826863B1 (en) | 2001-07-04 | 2003-09-26 | Jacques Seguin | ASSEMBLY FOR PLACING A PROSTHETIC VALVE IN A BODY CONDUIT |
US7377938B2 (en) | 2001-07-19 | 2008-05-27 | The Cleveland Clinic Foundation | Prosthetic cardiac value and method for making same |
FR2828091B1 (en) | 2001-07-31 | 2003-11-21 | Seguin Jacques | ASSEMBLY ALLOWING THE PLACEMENT OF A PROTHETIC VALVE IN A BODY DUCT |
US7097659B2 (en) | 2001-09-07 | 2006-08-29 | Medtronic, Inc. | Fixation band for affixing a prosthetic heart valve to tissue |
US6790237B2 (en) | 2001-10-09 | 2004-09-14 | Scimed Life Systems, Inc. | Medical stent with a valve and related methods of manufacturing |
US6893460B2 (en) | 2001-10-11 | 2005-05-17 | Percutaneous Valve Technologies Inc. | Implantable prosthetic valve |
US7201771B2 (en) | 2001-12-27 | 2007-04-10 | Arbor Surgical Technologies, Inc. | Bioprosthetic heart valve |
US20030130729A1 (en) | 2002-01-04 | 2003-07-10 | David Paniagua | Percutaneously implantable replacement heart valve device and method of making same |
AU2003225291A1 (en) | 2002-05-10 | 2003-11-11 | Cordis Corporation | Method of making a medical device having a thin wall tubular membrane over a structural frame |
US7041132B2 (en) | 2002-08-16 | 2006-05-09 | 3F Therapeutics, Inc, | Percutaneously delivered heart valve and delivery means thereof |
US8551162B2 (en) | 2002-12-20 | 2013-10-08 | Medtronic, Inc. | Biologically implantable prosthesis |
US7399315B2 (en) | 2003-03-18 | 2008-07-15 | Edwards Lifescience Corporation | Minimally-invasive heart valve with cusp positioners |
US7159593B2 (en) | 2003-04-17 | 2007-01-09 | 3F Therapeutics, Inc. | Methods for reduction of pressure effects of cardiac tricuspid valve regurgitation |
US7175656B2 (en) | 2003-04-18 | 2007-02-13 | Alexander Khairkhahan | Percutaneous transcatheter heart valve replacement |
JP4940388B2 (en) | 2003-04-24 | 2012-05-30 | クック メディカル テクノロジーズ エルエルシー | Prosthetic valve prosthesis with improved hydrodynamic properties |
US7201772B2 (en) | 2003-07-08 | 2007-04-10 | Ventor Technologies, Ltd. | Fluid flow prosthetic device |
EP1653888B1 (en) | 2003-07-21 | 2009-09-09 | The Trustees of The University of Pennsylvania | Percutaneous heart valve |
DE10334868B4 (en) | 2003-07-29 | 2013-10-17 | Pfm Medical Ag | Implantable device as a replacement organ valve, its manufacturing process and basic body and membrane element for it |
EP1659992B1 (en) | 2003-07-31 | 2013-03-27 | Cook Medical Technologies LLC | Prosthetic valve devices and methods of making such devices |
US8021421B2 (en) | 2003-08-22 | 2011-09-20 | Medtronic, Inc. | Prosthesis heart valve fixturing device |
EG24012A (en) | 2003-09-24 | 2008-03-23 | Wael Mohamed Nabil Lotfy | Valved balloon stent |
US20050075729A1 (en) | 2003-10-06 | 2005-04-07 | Nguyen Tuoc Tan | Minimally invasive valve replacement system |
US7556647B2 (en) | 2003-10-08 | 2009-07-07 | Arbor Surgical Technologies, Inc. | Attachment device and methods of using the same |
US7070616B2 (en) | 2003-10-31 | 2006-07-04 | Cordis Corporation | Implantable valvular prosthesis |
US7186265B2 (en) | 2003-12-10 | 2007-03-06 | Medtronic, Inc. | Prosthetic cardiac valves and systems and methods for implanting thereof |
US7261732B2 (en) | 2003-12-22 | 2007-08-28 | Henri Justino | Stent mounted valve |
CN101947146B (en) | 2003-12-23 | 2014-08-06 | 萨德拉医学公司 | Relocatable heart valve |
US7780725B2 (en) | 2004-06-16 | 2010-08-24 | Sadra Medical, Inc. | Everting heart valve |
US8246675B2 (en) | 2003-12-23 | 2012-08-21 | Laboratoires Perouse | Kit for implanting in a duct |
US8828078B2 (en) | 2003-12-23 | 2014-09-09 | Sadra Medical, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US9526609B2 (en) | 2003-12-23 | 2016-12-27 | Boston Scientific Scimed, Inc. | Methods and apparatus for endovascularly replacing a patient's heart valve |
US8840663B2 (en) | 2003-12-23 | 2014-09-23 | Sadra Medical, Inc. | Repositionable heart valve method |
US20050137686A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical, A Delaware Corporation | Externally expandable heart valve anchor and method |
US8182528B2 (en) | 2003-12-23 | 2012-05-22 | Sadra Medical, Inc. | Locking heart valve anchor |
US20050137687A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical | Heart valve anchor and method |
US7597711B2 (en) | 2004-01-26 | 2009-10-06 | Arbor Surgical Technologies, Inc. | Heart valve assembly with slidable coupling connections |
JP4403183B2 (en) | 2004-02-05 | 2010-01-20 | チルドレンズ・メディカル・センター・コーポレイション | Transcatheter delivery of replacement heart valves |
US7311730B2 (en) | 2004-02-13 | 2007-12-25 | Shlomo Gabbay | Support apparatus and heart valve prosthesis for sutureless implantation |
US8430925B2 (en) | 2004-02-27 | 2013-04-30 | Cardiacmd, Inc. | Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same |
GB2427887B (en) | 2004-03-12 | 2008-07-30 | Schlumberger Holdings | Sealing system and method for use in a well |
EP1729685B1 (en) | 2004-03-31 | 2015-07-15 | Cook Medical Technologies LLC | Endoluminal graft with a prosthetic valve |
US20060025857A1 (en) | 2004-04-23 | 2006-02-02 | Bjarne Bergheim | Implantable prosthetic valve |
US20060052867A1 (en) | 2004-09-07 | 2006-03-09 | Medtronic, Inc | Replacement prosthetic heart valve, system and method of implant |
JP2008513060A (en) | 2004-09-14 | 2008-05-01 | エドワーズ ライフサイエンシーズ アーゲー | Device and method for treatment of heart valve regurgitation |
CA2583591C (en) | 2004-10-02 | 2018-10-30 | Christoph Hans Huber | Methods and devices for repair or replacement of heart valves or adjacent tissue without the need for full cardiopulmonary support |
US20060085060A1 (en) | 2004-10-15 | 2006-04-20 | Campbell Louis A | Methods and apparatus for coupling an allograft tissue valve and graft |
US7641687B2 (en) | 2004-11-02 | 2010-01-05 | Carbomedics Inc. | Attachment of a sewing cuff to a heart valve |
US20060122634A1 (en) | 2004-12-03 | 2006-06-08 | Ino Takashi H | Apparatus and method for delivering fasteners during valve replacement |
US7989157B2 (en) | 2005-01-11 | 2011-08-02 | Medtronic, Inc. | Solution for storing bioprosthetic tissue used in a biological prosthesis |
CA2593652A1 (en) | 2005-01-21 | 2006-08-17 | Innovia, Llc | Stent-valve and deployment catheter for use therewith |
US7717955B2 (en) | 2005-02-28 | 2010-05-18 | Medtronic, Inc. | Conformable prosthesis for implanting two-piece heart valves and methods for using them |
US8083793B2 (en) | 2005-02-28 | 2011-12-27 | Medtronic, Inc. | Two piece heart valves including multiple lobe valves and methods for implanting them |
US7513909B2 (en) | 2005-04-08 | 2009-04-07 | Arbor Surgical Technologies, Inc. | Two-piece prosthetic valves with snap-in connection and methods for use |
SE531468C2 (en) | 2005-04-21 | 2009-04-14 | Edwards Lifesciences Ag | An apparatus for controlling blood flow |
US7914569B2 (en) | 2005-05-13 | 2011-03-29 | Medtronics Corevalve Llc | Heart valve prosthesis and methods of manufacture and use |
US20060271172A1 (en) | 2005-05-16 | 2006-11-30 | Hassan Tehrani | Minimally Invasive Aortic Valve Replacement |
EP1883375B1 (en) | 2005-05-24 | 2016-12-07 | Edwards Lifesciences Corporation | Rapid deployment prosthetic heart valve |
US8211169B2 (en) | 2005-05-27 | 2012-07-03 | Medtronic, Inc. | Gasket with collar for prosthetic heart valves and methods for using them |
US7238200B2 (en) | 2005-06-03 | 2007-07-03 | Arbor Surgical Technologies, Inc. | Apparatus and methods for making leaflets and valve prostheses including such leaflets |
US20070162111A1 (en) | 2005-07-06 | 2007-07-12 | The Cleveland Clinic Foundation | Apparatus and method for replacing a cardiac valve |
EP1919397B1 (en) | 2005-07-13 | 2013-01-02 | Medtronic, Inc. | Two-piece percutaneous prosthetic heart valves |
US7611534B2 (en) | 2005-08-25 | 2009-11-03 | The Cleveland Clinic Foundation | Percutaneous atrioventricular valve and method of use |
US20070078510A1 (en) | 2005-09-26 | 2007-04-05 | Ryan Timothy R | Prosthetic cardiac and venous valves |
US20070129794A1 (en) | 2005-10-05 | 2007-06-07 | Fidel Realyvasquez | Method and apparatus for prosthesis attachment using discrete elements |
DE102005051849B4 (en) | 2005-10-28 | 2010-01-21 | JenaValve Technology Inc., Wilmington | Device for implantation and attachment of heart valve prostheses |
DE102005052628B4 (en) | 2005-11-04 | 2014-06-05 | Jenavalve Technology Inc. | Self-expanding, flexible wire mesh with integrated valvular prosthesis for the transvascular heart valve replacement and a system with such a device and a delivery catheter |
JP4982502B2 (en) | 2005-12-07 | 2012-07-25 | メドトロニック,インコーポレイテッド | Coupling system for a two-piece heart valve assembly |
US20070142907A1 (en) | 2005-12-16 | 2007-06-21 | Micardia Corporation | Adjustable prosthetic valve implant |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
US7967857B2 (en) | 2006-01-27 | 2011-06-28 | Medtronic, Inc. | Gasket with spring collar for prosthetic heart valves and methods for making and using them |
US8147541B2 (en) | 2006-02-27 | 2012-04-03 | Aortx, Inc. | Methods and devices for delivery of prosthetic heart valves and other prosthetics |
WO2007106755A1 (en) | 2006-03-10 | 2007-09-20 | Arbor Surgical Technologies, Inc. | Valve introducers and methods for making and using them |
US7625403B2 (en) | 2006-04-04 | 2009-12-01 | Medtronic Vascular, Inc. | Valved conduit designed for subsequent catheter delivered valve therapy |
US7591848B2 (en) | 2006-04-06 | 2009-09-22 | Medtronic Vascular, Inc. | Riveted stent valve for percutaneous use |
US7740655B2 (en) | 2006-04-06 | 2010-06-22 | Medtronic Vascular, Inc. | Reinforced surgical conduit for implantation of a stented valve therein |
US20070239269A1 (en) | 2006-04-07 | 2007-10-11 | Medtronic Vascular, Inc. | Stented Valve Having Dull Struts |
WO2007130880A1 (en) | 2006-04-29 | 2007-11-15 | Arbor Surgical Technologies, Inc | Guide shields for multiple component prosthetic heart valve assemblies and apparatus and methods for using them |
WO2007130881A2 (en) | 2006-04-29 | 2007-11-15 | Arbor Surgical Technologies, Inc. | Multiple component prosthetic heart valve assemblies and apparatus and methods for delivering them |
US7534261B2 (en) | 2006-10-02 | 2009-05-19 | Edwards Lifesciences Corporation | Sutureless heart valve attachment |
WO2008073582A2 (en) | 2006-10-27 | 2008-06-19 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
US8147504B2 (en) | 2007-05-05 | 2012-04-03 | Medtronic, Inc. | Apparatus and methods for delivering fasteners during valve replacement |
US8652202B2 (en) | 2008-08-22 | 2014-02-18 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
US20160030165A1 (en) | 2013-03-15 | 2016-02-04 | Endoluminal Sciences Pty Ltd | Means for Controlled Sealing of Endovascular Devices |
CA2907013A1 (en) | 2013-03-15 | 2014-11-13 | Yoram Richter | System and method for sealing percutaneous valve |
-
2014
- 2014-11-05 US US14/533,922 patent/US20150122687A1/en not_active Abandoned
-
2017
- 2017-10-24 US US15/792,441 patent/US10722316B2/en active Active
-
2020
- 2020-07-24 US US16/938,899 patent/US20200352670A1/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5549663A (en) * | 1994-03-09 | 1996-08-27 | Cordis Corporation | Endoprosthesis having graft member and exposed welded end junctions, method and procedure |
US20030100920A1 (en) * | 1999-07-28 | 2003-05-29 | Akin Jodi J. | Devices and methods for interconnecting conduits and closing openings in tissue |
US7220274B1 (en) * | 2003-03-21 | 2007-05-22 | Quinn Stephen F | Intravascular stent grafts and methods for deploying the same |
US20050137690A1 (en) * | 2003-12-23 | 2005-06-23 | Sadra Medical | Low profile heart valve and delivery system |
US8517027B2 (en) * | 2004-09-03 | 2013-08-27 | Boston Scientific Scimed, Inc. | Reversible vessel seal |
US20110004299A1 (en) * | 2006-02-18 | 2011-01-06 | The Cleveland Clinic Foundation | Apparatus and method for replacing a diseased cardiac valve |
US20070244544A1 (en) * | 2006-04-14 | 2007-10-18 | Medtronic Vascular, Inc. | Seal for Enhanced Stented Valve Fixation |
US20090088836A1 (en) * | 2007-08-23 | 2009-04-02 | Direct Flow Medical, Inc. | Translumenally implantable heart valve with formed in place support |
US20090164005A1 (en) * | 2007-12-21 | 2009-06-25 | Edwards Lifesciences Corporation | Capping Bioprosthetic Tissue to Reduce Calcification |
US8839957B2 (en) * | 2010-02-15 | 2014-09-23 | Michael C. Murad | Prosthetic heart valve packaging system |
US20110214398A1 (en) * | 2010-03-05 | 2011-09-08 | Edwards Lifesciences Corporation | Dry Prosthetic Heart Valve Packaging System |
US20110311493A1 (en) * | 2010-06-17 | 2011-12-22 | Dove Jeffrey S | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
US20120290079A1 (en) * | 2011-05-12 | 2012-11-15 | Edwards Lifesciences Corporation | Mitral heart valve holder and storage system |
US20130190857A1 (en) * | 2011-09-09 | 2013-07-25 | Endoluminal Sciences Pty Ltd. | Means for controlled sealing of endovascular devices |
US20130197622A1 (en) * | 2011-09-09 | 2013-08-01 | Endoluminal Sciences Pty Ltd | Means for Controlled Sealing of Endovascular Devices |
US20130331929A1 (en) * | 2011-09-09 | 2013-12-12 | Endoluminal Sciences Pty Ltd. | Means for Controlled Sealing of Endovascular Devices |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170266002A1 (en) * | 2007-01-19 | 2017-09-21 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
US11547560B2 (en) * | 2007-01-19 | 2023-01-10 | The Cleveland Clinic Foundation | Implantable cardiovascular valve |
US10166097B2 (en) | 2009-09-29 | 2019-01-01 | Edwards Lifesciences Cardiaq Llc | Replacement heart valve and method |
US20170209261A1 (en) * | 2011-09-12 | 2017-07-27 | Highlife Sas | Transcatheter valve prosthesis |
US10828157B2 (en) * | 2011-09-12 | 2020-11-10 | Highlife Sas | Transcatheter valve prosthesis |
US20210015605A1 (en) * | 2011-09-12 | 2021-01-21 | Highlife Sas | Transcatheter valve prosthesis |
US11642220B2 (en) * | 2011-09-12 | 2023-05-09 | Highlife Sas | Transcatheter valve prosthesis |
US20170224480A1 (en) * | 2013-02-01 | 2017-08-10 | Medtronic, Inc. | Anti-Paravalvular Leakage Component for a Transcatheter Valve Prosthesis |
US9675451B2 (en) * | 2013-02-01 | 2017-06-13 | Medtronic CV Luxembourg S.a.r.l. | Anti-paravalvular leakage component for a transcatheter valve prosthesis |
US11690713B2 (en) | 2013-02-01 | 2023-07-04 | Medtronic CV Luxembourg S.a.r.l. | Anti-paravalvular leakage component for a transcatheter valve prosthesis |
US20140243966A1 (en) * | 2013-02-01 | 2014-08-28 | Medtronic, Inc. | Anti-Paravalvular Leakage Component for a Transcatheter Valve Prosthesis |
US10702379B2 (en) * | 2013-02-01 | 2020-07-07 | Medtronic CV Luxembourg S.a.r.l. | Anti-paravalvular leakage component for a transcatheter valve prosthesis |
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
US10888420B2 (en) | 2016-03-14 | 2021-01-12 | Medtronic Vascular, Inc. | Stented prosthetic heart valve having a wrap and delivery devices |
US10179045B2 (en) | 2016-03-24 | 2019-01-15 | Medtronic Vascular, Inc. | Stented prosthetic heart valve having wrap and methods of delivery and deployment |
US9974649B2 (en) | 2016-03-24 | 2018-05-22 | Medtronic Vascular, Inc. | Stented prosthetic heart valve having wrap and methods of delivery and deployment |
US10433993B2 (en) | 2017-01-20 | 2019-10-08 | Medtronic Vascular, Inc. | Valve prosthesis having a radially-expandable sleeve integrated thereon for delivery and prevention of paravalvular leakage |
US11666443B2 (en) | 2017-01-20 | 2023-06-06 | Medtronic Vascular, Inc. | Valve prosthesis having a radially expandable sleeve integrated thereon for delivery and prevention of paravalvular leakage |
US11903808B2 (en) * | 2017-05-02 | 2024-02-20 | Medtronic Vascular, Inc. | Assemblies for sterilizing a wet stored prosthetic heart valve |
US20210315679A1 (en) * | 2017-05-02 | 2021-10-14 | Medtronic Vascular, Inc. | Assemblies and methods of sterilizing a wet stored prosthetic heart valve |
US11284984B2 (en) * | 2017-05-02 | 2022-03-29 | Medtronic Vascular, Inc. | Assemblies and methods of sterilizing a wet stored prosthetic heart valve |
US11344399B2 (en) | 2017-05-02 | 2022-05-31 | Medtronic Vascular, Inc. | Packaging for dry tissue prosthetic heart valve |
CN110769782A (en) * | 2017-05-12 | 2020-02-07 | 爱德华兹生命科学公司 | Prosthetic heart valve docking assembly |
US10869750B2 (en) * | 2018-09-10 | 2020-12-22 | Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen | Endovascular stent grafts and methods of using said stent grafts |
US20200078161A1 (en) * | 2018-09-10 | 2020-03-12 | Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen | Endovascular stent grafts and methods of using said stent grafts |
WO2022236928A1 (en) * | 2021-05-08 | 2022-11-17 | 上海臻亿医疗科技有限公司 | Anchoring device for cardiac implant prosthesis and cardiac implant prosthesis comprising same |
WO2022236929A1 (en) * | 2021-05-14 | 2022-11-17 | 上海臻亿医疗科技有限公司 | Heart valve prosthesis apparatus |
US11969329B2 (en) | 2022-05-03 | 2024-04-30 | Medtronic Vascular, Inc. | Packaging for dry tissue prosthetic heart valve |
Also Published As
Publication number | Publication date |
---|---|
US10722316B2 (en) | 2020-07-28 |
US20180042690A1 (en) | 2018-02-15 |
US20200352670A1 (en) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200352670A1 (en) | Bioprosthetic heart valves having adaptive seals to minimize perivalvular leakage | |
RU2644266C2 (en) | System and method for subdermal valve sealing | |
JP6661145B2 (en) | Stent valve delivery system for sealing an expandable stent | |
US10420658B2 (en) | Prosthesis seals and methods for sealing an expandable prosthesis | |
EP2772228B1 (en) | Prosthetic heart valve with expandable microspheres | |
ES2773174T3 (en) | Low Profile Transcatheter Heart Valve | |
JP2020065939A (en) | Improvement of transcatheter stent valves | |
US7563277B2 (en) | Removable covering for implantable frame projections | |
ES2616693T3 (en) | Collapsible and re-expandable prosthetic heart valve sleeve designs and complementary technological applications | |
JP6272915B2 (en) | Improvement of transcatheter stent valve | |
US20120172979A1 (en) | Methods for prosthetic valves formed with isotropic filter screen leaflets | |
WO2018050203A1 (en) | Heart implant | |
WO2007081820A1 (en) | Transcatheter delivery of a replacement heart valve | |
JP7254918B2 (en) | artificial heart valve | |
US20020123789A1 (en) | Stent cover | |
CN113853180A (en) | Hydrophilic skirt for paravalvular leak mitigation and fit and hug optimization for prosthetic heart valve implants | |
CN116459040A (en) | Artificial valve | |
EP1135081A1 (en) | Stent cover |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EDWARDS LIFESCIENCES CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZENG, QINGGANG;LIMSAKOUNE, CHACPHET;KO, DIANA E.;AND OTHERS;REEL/FRAME:034498/0609 Effective date: 20131115 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |